Abstract: Cervical cancer is the second most common gynecological malignancy globally; it seriously endangers women’s health because of its high morbidity and mortality. Conventional treatments are prone to drug resistance, recurrence and metastasis. Therefore, there is an urgent need to develop new drugs with high efficacy and low side effects to prevent and treat cervical cancer. In recent years, plant-derived natural products have been evaluated as potential anticancer drugs that preferentially kill tumor cells without severe adverse effects. A growing number of studies have shown that natural products can achieve practical anti-cervical-cancer effects through multiple mechanisms, including inhibition of tumor-cell proliferation, induction of apoptosis, suppression of angiogenesis and telomerase activity, enhancement of immunity and reversal of multidrug resistance. This paper reviews the therapeutic effects and mechanisms of plant-derived natural products on cervical cancer and provides references for developing anti-cervical-cancer drugs with high efficacy and low side effects.

Keywords: plant-derived natural products; cervical cancer; molecular mechanisms; treatment

1. Introduction

Cervical cancer is one of the second most common gynecologic malignancies in the world, with more than 570,000 women diagnosed with cervical cancer and 311,000 deaths annually worldwide [1]. However, persistent high-risk human papillomavirus (HPV) infection is the primary causative agent of cervical carcinogenesis, especially HPV16 and HPV18, which cause 70% to 72% of invasive cervical cancers. HPV contains two oncoproteins (E6 and E7) that play an essential role in the cervical cancer development and progression [2,3]. Currently, the main treatments for cervical cancer include surgical resection, radiotherapy, local targeted therapy and immunotherapy. Although traditional therapies are effective for early stage cervical cancer, they have limited efficacy for locally staged and metastatic cervical cancer due to severe side effect, drug resistance, multiple recurrences and metastases [4,5]. Therefore, there is an urgent need to develop drugs with a better safety profile and higher efficacy for cervical cancer treatment.

In recent years, plant-derived natural products have been considered as the most promising candidates for oncology therapies. They can preferentially kill tumor cells with low toxic effect on normal cells. This is attributed to their chemical diversity, structural complexity, inherent biological activity and low side effects [6,7]. A variety of plant-derived natural products with antitumor activities have been identified, such as flavonoids, terpenoids, alkaloids and phenols, which can inhibit tumor-cell proliferation, induce apoptosis, reduce telomerase activity, suppress angiogenesis, improve immune function, reverse multidrug resistance, etc. [8–10]. In this paper, we review the recent studies on the role and mechanisms of plant-derived natural products in the treatment of cervical cancer.

2. Methods

We collected the relevant experimental works in the literature published in the last five years that elucidate the anticancer effects of natural products on cervical cancer, using
PUBMED (including Medline) and the Google Scholar database. Upon searching for the appropriate studies, we used “natural product, cervical cancer” as keywords. After completing the initial search, we removed duplicate works from the literature. Chemical structures of compounds derived from natural products were cited from the NCBI PubChem website, available online: https://pubmed.ncbi.nlm.nih.gov/ (accessed on 10 June 2021).

3. Flavonoids

Flavonoids are phenolic phytochemicals that are commonly found in fruits, vegetables and plant-based beverages (e.g., green tea and wine) [11]. More than 8000 species have been identified and isolated from plants. Their structures consist of C\(_6\)-C\(_3\)-C\(_6\) skeletons labeled with A, B and C rings, which can be classified into flavones, flavanones, flavonols, flavanols, isoflavones and anthocyanidins based on their structural diversity [12,13]. Many studies have reported that flavonoids have a significant role in tumor prevention and treatment attributed to their wide range of biological activities, such as anti-inflammatory, antioxidant, anti-hyperlipidemic, anti-fatigue, anti-aging, etc. [14–16]. In addition, they can induce apoptosis of tumor cells by inhibiting various pro-cancer pathways and genes in tumor cells.

3.1. Flavones

Scutellaria baicalensis is one of the versatile herbs traditionally and has been used in China to treat inflammatory diseases, hypertension, cardiovascular diseases, bacterial and viral infections. A large amount of evidence suggests that S. baicalensis also has potent anticancer activity, and its main bioactive components are baicalein, Wogonin, and baicalin [17,18]. Baicalein is a flavonoid derived from the roots of S. baicalensis and has a variety of pharmacological activities, which can inhibit cell proliferation and migration; induce apoptosis and cell-cycle arrest [19]. Cyclin D1 is a potential therapeutic target for cervical cancer. Baicalein inhibits cyclin D1 overexpression and arrests the cell cycle at G0/G1 phase through Wnt/β-catenin and protein kinase B/glycogen synthase kinase-3β (AKT/GSK-3β) signaling pathways to suppress proliferation and induce apoptosis of human cervical cancer HeLa and SiHa cells [20,21]. According to reports, baicalein inhibited tumor necrosis factor alpha (TNF-α)-induced the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the expression of apoptosis protein 1 (cIAP-1), cIAP-2, FLIP, B-cell lymphoma 2 (Bcl-2), matrix metalloproteinase 2 (MMP2), MMP9, first apoptosis signal receptor (Fas), FasL, caspase 8 and vascular endothelial factor (VEGF) in a dose-dependent manner to suppress HeLa cell invasion and migration. On the other hand, baicalein blocked TNF-α-induced nuclear translocation of p65 through inhibiting the phosphorylation and degradation of the inhibitory subunit of NF-κB (IκBα), activated caspase 8 and promoted the cleavage of poly (ADP-ribose) polymerase (PARP) expression to induce apoptosis in HeLa cells. In addition, baicalein had strong anti-inflammatory activity by inhibiting the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) and p38, which reduced the expression of the inflammatory cytokines, including interleukin 8 (IL-8) and monocyte chemoattractant protein 1 (MCP1) [22–24]. Moreover, baicalein inactivated the AKT/mammalian target of rapamycin (mTOR) pathway by targeting the circH1AT1/miR-19a-3p axis to inhibit the proliferation of cervical cancer cells [25]. Another study illustrated that baicalein significantly suppressed cervical cancer xenograft tumor growth and metastasis in vivo through intraperitoneally injecting 10 mg/kg/d baicalein for four weeks. It was also reported that baicalein downregulated the expression of long non-coding RNA (lncRNA) in a dose- and time-dependent manner and named baicalein down-regulated long non-coding RNA (BDLNR). As it physically bound itself to Y-box binding protein 1 (YBX1), recruited YBX1 to the PIK3CA promoter, and it mediated the anti-cancer effects of baicalein in cervical cancer via activating PI3K/Akt pathway [26]. It is suggested that BDLNR may be a potential therapeutic target to enhance the anticancer effect of baicalein.
Wogonin is a natural monoflavonoid with the potential for selective tumor therapy in vitro and in vivo [27]. Wogonin could decrease the expression of HPV oncoproteins E6 and E7 and induce apoptosis in SiHa and CaSki cells through the mitochondria-mediated pathway, thus reducing mitochondrial membrane potential (MMP); elevating the Bcl-2-associated X protein (Bax)/Bcl-2 expression ratio; leading to cytochrome c (Cyt c) release; and triggering the cleavage of caspase 3, caspase 9 and PARP [28]. Wogonin also inhibited HeLa cell proliferation by inducing G1-phase cell-cycle arrest and apoptosis via decreasing the expression of cyclin D1, cyclin-dependent kinase 4 (CDK 4), pRb and nuclear transcription factor E2F-1, as well as increasing the expression of cyclin-dependent kinase inhibitor 1A/CDK-interacting protein 1(p21cip1) at the mRNA and protein levels through a p53-dependent mechanism [29]. Moreover, wogonin can enhance the effect of cisplatin on the induction of cancer cell apoptosis through reactive oxygen species (ROS)-dependent mechanism [30]. The results indicate that wogonin is a potential anticancer agent.

Apigenin is an edible natural flavonoid found in various dietary plant foods, such as vegetables and fruits [31]. It has a strong inhibitory effect on tumor-cell viability in vivo and in vitro. Its derivative apigenin 7-glucoside has anti-inflammatory, antioxidant and anticancer activities [32]. Apigenin 7-glucoside significantly suppressed the proliferation of HeLa cells, and the IC$_{50}$ value at 48 h was 47.26 µmol/L. It induced apoptosis in HeLa cells through the death receptor pathway and the mitochondrial pathway, which effectively increased the expression of ROS, Fas, FasL, TNF-α, TNF-r1, Fas-associated death domain (FADD), TNF receptor-associated death domain (TRADD), caspase 3 and caspase 9 and decreased the expression of pro-caspase 8, caspase 10, Bcl-2 and Bcl-2 extra-large protein (Bcl-xl). Additionally, apigenin 7-glucoside treatment increased p16 INK4A expression and reduced Cyclin (A, D, E) and CDK2/6 expression. Meanwhile, it inhibited HeLa cell migration by targeting the phosphatase and tensin homolog (PTEN)/PI3K/AKT pathway [33]. Some studies reported that apigenin showed selective sensitivity for human cervical cancer HeLa, SiHa, CaSki and C33A cells with IC$_{50}$ values of 10, 68, 76 and 40 µmol/L, respectively. Apigenin also induced mitochondrial redox damage, decreased MMP and lipid peroxidation and inhibited the migration and invasion of cervical cancer cells [34]. Zhang et al. found that Apigenin suppressed cervical tumor growth in vivo by attenuating histamine-induced abnormal estrogen receptor signaling by increasing the estrogen receptor β/estrogen receptor α (ERβ/ERα) ratio when tumor model mice were administrated intraperitoneally with 100 mg/kg apigenin +1 mg/kg histamine every 3 d. Moreover, apigenin induced autophagy and apoptosis in HeLa cells through the PI3K/AKT/mTOR signaling pathway [35]. Consequently, apigenin and its derivatives may prevent the development and progression of cervical cancer and represent promising drugs for cervical cancer therapy.

Luteolin is a common plant flavonoid found in various plants, including fruits, vegetables and medicinal herbs. Luteolin-rich plants have been used to treat multiple diseases, such as hypertension, cancer and inflammation [36,37]. Luteolin could dose-dependently reduce the proliferation of HeLa cells with IC$_{50}$ value of 21.8 µmol/L. Luteolin induced apoptosis and G2/M phase cell-cycle arrest in HeLa cells by downregulating UHRF1 and DNA methyltransferase 1 (DNMT1) with a reduction of overall DNA methylation and upregulating p16 INK4A expression [38]. On the other hand, luteolin promoted apoptosis by inhibiting TNF-α-induced NF-κB activation, downregulating A20 and c-IAP1 gene expression and enhancing c-Jun N-terminal kinase (JNK) activity [39]. It was also reported that luteoloside inhibited HeLa cell proliferation by endogenous and exogenous pathways, which increased the ratio of Bax/Bcl-2 to reduce MMP and release Cyt c, upregulated Fas expression and activated caspase 8 and caspase 3. At the same time, luteoloside inhibited mTOR and activated p38 mitogen-activated protein kinase (MAPK) signaling pathways to exert anti-cervical-cancer effects [40]. In addition, luteolin combined with TNF-related apoptosis-inducing ligand (TRAIL) synergistically induced apoptosis in HeLa cells through upregulation of death receptor 5 (DR5) and Bid cleavage, and activation of caspase-8 [41]. These data suggest that luteolin may serve as a new therapeutic strategy for cervical cancer.
3.2. Flavanones

Citrus fruits are rich in flavonoids and are known for their health-promoting and chemopreventive properties. Naringin, a flavonoid glycoside, can be isolated from citrus fruits, such as orange, tangerine, lemon and lime, and has several pharmacological activities [42]. Naringin can significantly reduce cancer cell viability and proliferation without toxicity to normal tissue cells [43]. The IC\textsubscript{50} values of naringin for HeLa, SiHa and C33A cells after 24-h treatment were 793, 764 and 745 µmol/L, respectively, and showed a dose-dependent relationship. Naringin increased the level of endoplasmic reticulum (ER) stress sensors, phosphorylated eIF2\textalpha and activated the apoptosis-related protein CHOP and other associated pro-apoptotic proteins (PARP1). Importantly, naringin also blocked the \beta-catenin signaling pathway by decreasing \beta-catenin (Ser576) and GSK-3\beta (Ser9) protein expression and phosphorylation and induced cell-cycle arrest at G0/G1 phase by increasing the expression of cell-cycle checkpoint proteins p21/cip and p27/kip to trigger apoptosis in cervical cancer cells [44]. Another study reported that naringin promoted the expressions of caspases (3, 8 and 9), p53, Bax, Fas death receptor and its adaptor protein FADD to induce apoptosis in HeLa cells through the death receptor pathway and the mitochondrial pathway. The activation of the exogenous pathway was associated with increased caspase 8, which activated the death receptor by cleaving Bid into tBid and the crosstalk between the death receptor and mitochondrial pathways [45]. Moreover, naringin also induced growth inhibition and apoptosis in HeLa cells by decreasing the expression of NF-\kappaBp65, COX-2 and caspase 1 [46]. The results suggest that naringin is a potentially effective drug for treating human cervical cancer.

Hesperidin is a citrus flavonoid and has various functions, including antioxidation, antitumor and anti-angiogenesis functions, which can protect mitochondrial membranes from free radical attack and inhibit tumor-cell migration and invasion [47,48]. Hesperetin inhibited the cell viability of SiHa cells in a dose- and time-dependent manner with IC\textsubscript{50} values of 650 µmol/L. Hesperetin induced cell-cycle arrest at G2/M phase and apoptosis in SiHa cells by death receptor and mitochondrial pathways, characterized by depolarizing MMP and increasing the expression of caspase 3, caspase 8, caspase 9, p53, Bax, Fas and FADD [49]. In addition, hesperidin inhibited HeLa cell proliferation and induced apoptosis through ER stress and mitochondria-mediated pathways via decreasing the expression of cyclin D1, cyclin E1 and CDK2, promoting Cyt c release, and activating the expression of apoptosis-inducing factor (AIF), GADD153/CHOP and glucose-regulated protein of 78 kDa (GRP78) [50]. Hesperidin has potential in preventing and treating cervical cancer and may open new avenues for cancer treatment.

Silibinin is a bioactive polyphenolic flavonoid isolated from the fruits and seeds of \textit{silybum marianum}. It has been used to treat various diseases, especially the liver, gallbladder and kidney [51,52]. \textit{Silibinin} inhibited the growth of Hela and SiHa cells in a dose- and time-dependent manner, with IC\textsubscript{50} values of 332 and 275 µmol/L for HeLa cells, and 250 and 195 µmol/L for SiHa cells at 48 h and 72 h, respectively. It reduced ATP content, mtDNA copy number and MMP, activated the dynamin-related protein 1(Drp1)-mediated mitochondrial fission pathway, induced G2/M cell-cycle arrest through reducing the expression of CDK1, cyclin B1 and Cdc25C [53]. \textit{Silibinin} also suppressed angiogenesis and promoted apoptosis in HeLa cells through inhibiting the mTOR/p70S6K/4E-BP1 signaling pathway and decreasing the accumulation and transcriptional activity of hypoxia-inducible factor-1\alpha (HIF-1\alpha) and the release of VEGF. Moreover, the anti-angiogenic ability of \textit{silibinin} was enhanced by blocking AKT activation through PI3K/AKT inhibitor LY294002 [54]. At the same time, \textit{silibinin} induced apoptosis in HeLa cells through the mitochondrial pathway and the death-inducing pathway, resulting in decreased expression of CDK1 and CDK2 proteins and increased ratio of Bax/Bcl-2, followed by Cyt c release and activation of caspase 9, as well as increased expression of Fas and FasL and activation of caspase 8 [55]. The evidence has shown that hydroxyl radical (-OH) is the main form of \textit{silibinin}-induced ROS [56]. \textit{Silibinin} inhibits HeLa cell growth by activating apoptotic vesicles and caspase 3, and promoting the phosphorylation of p53 and JNK in a dose-dependent manner.
p53 subsequently interferes with mitochondrial function through the p53-upregulated modulator of apoptosis (PUMA) pathway, which upregulates the Bax/Bcl-2 ratio, reduces MMP and increases ROS production. Then ROS induces autophagy and apoptosis in HeLa cells. Furthermore, p53-mediated glutathione (GSH) depletion significantly enhanced the cytotoxicity of NO in HeLa cells [57,58]. It may be a classical candidate for the design of anticancer drugs.

3.3. Flavonols

Kaempferol is a natural flavonol and widely distributes in many plant families. The growing evidence has shown that kaempferol is a potential cancer therapeutic agent with potent antitumor, anti-inflammatory and antioxidant properties [59]. It inhibited SiHa cell growth and proliferation in a dose- and time-dependent manner, and promoted SiHa cell apoptosis by disrupting MMP and elevating intracellular free Ca\(^{2+}\) concentration, which caused shrinkage of spindle-shaped SiHa cells and damage of their microtubule networks [60]. Another study showed that Kaempferol inhibited HeLa cell growth in a time- and concentration-dependent manner and the IC\(_{50}\) value was 10.48 \(\mu\)mol/L at 72 h, while it had weak toxicity for normal cells with IC\(_{50}\) value of 707 \(\mu\)mol/L at 72 h. It induced apoptosis and senescence in HeLa cells by inhibiting PI3K/AKT pathway and human telomerase reverse transcriptase (hTERT) expression and promoting the p53 pathway [61]. Telomerase is considered a new and potentially selective target for tumor therapy. Telomerase inhibition by kaempferol may provide a safe and effective approach for the treatment of cervical cancer. Additionally, overexpression of P-glycoprotein (P-gp) causes efflux of chemotherapeutic drugs from cells and is considered to be one of the crucial mechanisms of multidrug resistance (MDR) in cancer [62]. It was reported that kaempferol significantly decreased the activity and function of P-gp in MDR human cervical cancer KB-V1 cells in a dose-dependent manner, reduced drug efflux, improved sensitivity to chemotherapeutic drugs vinblastine and paclitaxel as well as cytotoxicity, which in turn induced apoptosis and reversed MDR in KB-V1 cells [63]. Kaempferol might be a potential candidate for the prevention and treatment of cancer due to its safety and low-cost advantages.

Quercetin is a dietary polyphenolic compound with wide distribution in vegetables and fruits and has various activities, including anti-allergic, anti-inflammatory and antitumor activities [64,65]. Quercetin can suppress tumor-cell proliferation and induce apoptosis, cell-cycle arrest and DNA damage through intrinsic apoptosis pathway, which involved in PI3K, MAPK and Wnt [66]. Priyadarshini et al. showed that quercetin could target both opposing signaling pathways, p53 and NF-\(\kappa\)B to inhibit the proliferation of HeLa cells [67]. Quercetin induced apoptosis of HeLa and SiHa cells by blocking the interaction of E6/E6AP complex, reactivating p53 and upregulating the expression of transcriptional target p21 [68]. Further, quercetin promoted apoptosis and reduced migration of HeLa cells within 18 h by downregulating the expression of AKT and Bcl-2, and blocked the cell cycle at the G2/M phase. The accumulation of ROS increased Cyt c release and MMP depolarization and activated caspase 3, which in turn exhibited significant anti-proliferative and pro-apoptotic effects on HeLa cells [69]. Interestingly, the combination of quercetin with other chemical agents effectively enhanced the antitumor effect. Quercetin inhibited the viability of HeLa and SiHa cells in a dose- and time-dependent manner, with an IC\(_{50}\) of 30 \(\mu\)mol/L for HeLa cells at 24 h and 50 \(\mu\)mol/L for SiHa cells at 48 h. Treatment with cisplatin or quercetin alone did not reduce the expression of MMP2 protein in cervical cancer cells but their combination significantly decreased MMP2 expression, which inhibited the migration and invasion of cervical cancer cells. Meanwhile, quercetin enhanced the chemosensitivity of cervical cancer cells by downregulating the expression of P-gp and methyltransferase-like 3 (METTL3), which mediated HeLa cell proliferation and apoptosis [70]. Quercetin also increased the sensitivity of HeLa cells to cisplatin by inhibiting the expression of the multidrug resistance-associated protein (MRP) and heat
shock protein Hsp72, which induced apoptosis and reversed cellular resistance [71]. These studies provided the experimental basis for the treatment of cisplatin-resistant patients.

Fisetin is a natural flavonols found in vegetables, fruits and nuts and has antitumor, anti-invasive, anti-angiogenic, antidiabetic, cardioprotective and neuroprotective activities [72,73]. Fisetin suppressed urokinase-type plasminogen activator (u-PA) expression by blocking the phosphorylation of p38 MAPK and the nuclear translocation of NF-κB, which inhibited the migration and invasion of SiHa cells. Moreover, the addition of the p38 MAPK inhibitor SB203580 further enhanced the inhibitory effect of fisetin on u-PA activity and expression [74]. It was also reported that fisetin not only promoted apoptosis protease activating factor-1 (Apaf-1) expression and Cyt c release to activate caspase 3 and caspase 9 but also inhibited ERK1/2 phosphorylation, COX-2 expression and prostaglandin E2 (PGE2) production by blocking the NF-κB/p300 signaling pathway, which in turn promoted HeLa cell apoptosis [75]. Furthermore, fisetin significantly inhibited the growth rate of tumors with inhibition rates of 82.65% and 92.62% in a mouse model of HeLa cell line injection without significant side effects [76]. It was also experimentally proven that fisetin combined with sorafenib could activate the DR5-mediated death receptor pathway and mitochondria-dependent pathway, which upregulated Bax/Bcl-2 ratio and promoted MMP depolarization, caspase 3/caspase 8 activation and PARP cleavage to induce apoptosis in HeLa cells [77]. Fisetin is expected to be an anticancer drug for the clinical treatment of cervical cancer.

3.4. Flavanols

Green tea (Camellia sinensis) is one of the most commonly used herbs globally and is widely known for its effectiveness in preventing chronic diseases and tumors. This is mainly attributed to the biologically active catechin compounds in green tea, such as (−)-epigallocatechin gallate (EGCG), (−)-epigallocatechin 3-gallate (ECG), (−)-epigallocatechin (EGC) and (+) catechin. Among them, EGCG is the main component of catechins and has substantial antioxidative, antitumor and anti-angiogenic effects [78,79]. After treatment with 150 and 300 µg/mL of catechin for 72 h, apoptosis rates of SiHa cells reached 31.62% and 34.8%, with an IC_{50} value of 196.07 µg/mL. In addition, catechin inhibited the proliferation and induced apoptosis of SiHa cells partly by regulating TP53 and caspase 3, caspase 8 and caspase 9 [80]. EGCG concentration- and time-dependently inhibited HeLa cell proliferation with an IC_{50} value of 20 µg/mL. EGCG inhibited the activation of AKT and NF-κB by blocking the phosphorylation and degradation of the inhibitory κBα and κBβ subunits to result in the downregulation of COX-2 expression. Furthermore, EGCG treatment led to mitochondrial dysfunction through increasing ROS production, p53 and Bax/Bcl-2 ratios to promote Cyt c release and activation of caspase cascade, which induced apoptosis in HeLa cells [81]. Recently, one study indicated that EGCG inhibited transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition (EMT) in Hela and SiHa cells via the ROS/Smad signaling pathway to inhibit cell migration and invasion [82]. Besides, EGCG can be used as an anti-angiogenic agent in the treatment of cervical cancer. EGCG significantly suppressed hypoxia and serum-induced accumulation of HIF-1α protein, as well as the expression of VEGF by blocking PI3K/Akt/mTOR and ERK1/2 signaling pathways, thereby inhibiting HeLa cell angiogenesis [83]. Meanwhile, EGCG enhances the sensitivity of cisplatin to cervical cancer cells by inhibiting the mTOR signaling pathway and the levels of p-p70S6K1 and p-4E-BP1, which in turn inhibits cell viability and induces apoptosis in HeLa cells [84]. It has also been shown that EGCG can induce apoptosis in HeLa cells by inhibiting telomerase activity [85]. It is suggested that telomerase inhibition may be one of the critical mechanisms of EGCG treatment.

3.5. Isoflavones

Genistein is considered the primary isoflavone in soy foods and is one of the most widely studied phytoestrogens in the Asian diet [86]. It was demonstrated that oral administration of 20 mg/kg of genistein exerted anti-proliferative and immunomodulatory
effects in cervical cancer mouse model, which promoted lymphocyte proliferation and lactate dehydrogenase (LDH) release, enhanced cytolytic activity and IFN-γ production, and thus induced protective antitumor immunity [87]. AKT signaling pathway plays a crucial role in controlling cell survival and apoptosis. Genistein enhanced the activity of cisplatin by inhibiting the expression of the AKT/mTOR pathway, p-p70s6k1 and p-4E-BP1, which led to the growth inhibition of cervical cancer cells [88]. Several studies indicated that inhibition of ERK or PI3K signaling pathways, along with activation of the p38-JNK pathway, shifted the balance toward apoptosis to result in higher levels of growth inhibition in a variety of tumor-cell lines [89,90]. Kim et al. found that genistein effectively inhibited the growth of HeLa and CaSki cells with IC$_{50}$ values of 20 and 60 µmol/L after 48 h. It inhibited cervical cancer cell proliferation by attenuating ERK1/2 activity and activating p38 MAPK, where AKT and JNK were partially involved in genistein-induced cancer cell growth inhibition [91]. In previous study, phytoestrogens have also been found to have an anti-tumor effect [92]. Genistein blocked the estrogen receptor-mediated PI3K/AKT-NF-κB signaling pathway and exerted antitumor effects by downregulating Bcl-2, VEGF, and tumor expression necrosis factor-associated receptor factor 1 (TRAF1) and promoting apoptosis in HeLa cells [93]. Genistein also induced apoptosis in HeLa cells via a p53-dependent pathway that disrupted the interaction between p53 and APE1 to increase the intracellular stability of p53 [94]. Therefore, genistein may have potential clinical application in the treatment of cervical cancer.

Puerarin is the main active ingredient extracted from *Pueraria tuberosa*, which has beneficial effects on cardiovascular diseases, neurological dysfunction, osteoporosis, liver injury and inflammation. Puerarin could effectively inhibit the production of pro-inflammatory cytokines in a variety of disease models [95]. Puerarin also inhibited tumor-cell proliferation in a dose- and time-dependent manner through inducing apoptosis and blocking cellular cyclin D1 expression by PI3K/AKT/NF-κB signaling pathway and exerting antitumor effects by downregulating Bcl-2, VEGF, and tumor expression necrosis factor-associated receptor factor 1 (TRAF1) and promoting apoptosis in HeLa cells [96]. Moreover, puerarin gavaged with 500 mg/kg for 15 d could increase the level of IL-2 and superoxide dismutase (SOD) activity in the plasma of U14 cervical cancer mice to enhance the immune function and antioxidant enzyme activity to scavenge excessive free radicals and reduce the damage of ROS in the body, thus achieving the antitumor effect [97]. Another study proved that puerarin (12.5–50 µmol/L) could inhibit HeLa cell proliferation and induce apoptosis through suppressing the β-catenin/Wnt/p53 signaling pathway [98]. Puerarin also significantly inhibited the expression of p-mTOR protein and activated caspase 3/9 in HeLa cells to reduce their proliferation and migration [99]. Thus, puerarin is expected to be a new drug for the prevention and treatment of cervical cancer.

Formononetin is a 7-hydroxy-40-methoxy herbal isoflavone isolated from *Pycnanthus angolensis*, red clovers, chickpea and other plants, and it possesses a variety of pharmacological activities, including antioxidant, chemopreventive, anti-inflammatory, anti-allergic, antibacterial and cardio-preventive effects [100,101]. According to the research, formononetin might mediate MRP (MRP1 and MRP2) inhibition through ROS while activate the mitochondrial apoptosis pathway, which resulted in MMP loss, increased Bax/Bcl-2 ratio and activation of caspase 3 and caspase 9. On the other hand, formononetin could also enhance the cytotoxicity of epirubicin in HeLa cells through the death receptor/caspase 8 apoptotic pathway [102]. Apart from this, formononetin inhibited HeLa cell proliferation in a concentration-dependent manner with an IC$_{50}$ value of 72.112 ± 5.671 µmol/L. Multi-walled carbon nanotubes are the best carrier of formononetin, and their combination can further enhance ROS-mediated mitochondrial dysfunction [103]. Moreover, oral gavage of 10 mg/kg of formononetin for 31 d significantly inhibited tumor growth in BALB/c mouse model inoculated with HeLa cells and reduced the expression of HIF-1α and VEGF in tumor tissues without severe side effects [104]. Moreover, formononetin (oral gavage of 20 and 40 mg/kg for 35 d) activated caspase 3 and upregulated the expression of Bax by inhibiting the transduction of PI3K/AKT signal pathway, accompanied by the release of Cyt c, and then induced apoptosis of HeLa cells [105]. It might be a potential drug for cervical cancer treatment.
3.6. Anthocyanins

Anthocyanins are natural pigments in the plant kingdom and endow plants their blue color and antioxidant potential. Anthocyanins are mainly found in small berries, such as strawberries, blueberries, cranberries, cherries and black raspberries. More than 600 structurally diverse anthocyanins have been identified in nature [106]. Cyanidin 3-O-glucoside is the main active component of anthocyanins, which has preventive and therapeutic effects on various diseases such as cerebral ischemia and Alzheimer’s disease [107]. The study showed that the inhibitory effects of cisplatin alone, cyanidin 3-O-glucoside alone and their combination on the proliferation of HeLa cells were 17.43%, 34.98% and 63.38%, respectively. Cyanidin 3-O-glucoside treatment downregulated the PI3K/AKT/mTOR signaling pathway; activated Bax, p53 and tissue inhibitor of metalloproteinase-1 (TIMP-1); decreased cyclin D1 and Bcl-2 expression; and blocked the cell cycle at the G1 phase, thus promoting apoptosis in HeLa cells [108]. Importantly, cyanidin 3-O-glucoside enhanced the sensitivity of HeLa cells to cisplatin. Their combination significantly inhibited the activities of SOD, catalase (CAT) and glutathione peroxidase (GSH-PX) by reducing the expression of NAD(P)H quinone dehydrogenase 1 (NQO1) and heme oxygenase-1 (HO-1), as well as modulating the nuclear factor E2-related factor 2 (Nrf2) signaling pathway to induce oxidative stress and apoptosis in HeLa cells [109]. It is suggested that cyanidin 3-O-glucoside may increase the antitumor activity of cisplatin to reduce the adverse effects associated with chemotherapy in cervical cancer and is a potential strategy for the treatment of cervical cancer.

The chemical structures of flavonoids are summarized in Figure 1. Table 1 summarizes their effects and mechanisms on cervical cancer.

![Chemical structures of flavonoids](image_url)
Table 1. Effect and mechanism of flavonoids on cervical cancer.

| Chemical Family | Molecule Name | Concentration | Cell Line | Mechanism |
|-----------------|---------------|---------------|-----------|-----------|
| **Flavones**    | Baicalein     | 100 µmol/L    | HeLa      | Increased: activation of caspase 3; PARP cleavage; Decreased: cIAP-1, cIAP-2, FLIP, Bcl-2, MMP2, MMP9; caspase 8, Fas, Fasl, VEGF, COX-2, cyclin D1, IL-8, MCP1; Inhibit NF-κB, ERK1/2; G1 phase cell block. |
|                 | Wogonin       | 0–100 µmol/L  | SiHa and CaSki | Increased: Bax, activation of caspase 3 and 9; Cyt c release; PARP cleavage; Decreased: MMP, Bcl-2 |
|                 | Apigenin 7-glucoside | IC<sub>50</sub> = 47.26 µmol/L | HeLa | Increased: ROS, TNF-α, TNF-αR1, RAD50; activation of caspase 3 and 9; Decreased: Bcl-2, Bcl-xl, Cyclin A, D1, E, CDK2/6; MMP, Inhibit PTEN/PERK/AKT; |
|                 | Apigenin      | IC<sub>50</sub> = 10, 68, 76 and 40 µmol/L | HeLa, SiHa, CaSki and C33A | Increased: ROS, H<sub>2</sub>O<sub>2</sub>; Decreased: MMP; |
|                 | Luteolin      | IC<sub>50</sub> = 21.8 µmol/L | HeLa | Increased: p53, Bax, Fas, FADD; activation of caspase 3 and 9; |
|                 | Naringin      | IC<sub>50</sub> = 750 µmol/L | SiHa | Increased: p53, Bax, Fas, FADD; activation of caspase 3 and 9; |
| **Flavanones**  | Hesperidin    | 0–100 µmol/L  | HeLa      | Increased: AIF, Cyt c release, activation of caspase 3; Decreased: MMP, cyclin D1, cyclin E1, CDK2/6, G0/G1 phase cell block. |
|                 | Silibinin     | IC<sub>50</sub> = 250,195 µmol/L | HeLa and SiHa | Increased: activation of Drp1; Decreased: ATP, MMP, ROS, CDK1, Cdc25C, cyclin B1; G2/M phase cell block. |
|                 | Kaempferol    | IC<sub>50</sub> = 10.48 µmol/L | HeLa | Increased: Bax, p53; Decreased: Bcl-2, NFκB, Inhibit P53/akt; |
| **Flavonols**   | Quercetin     | IC<sub>50</sub> = 110.38 ± 0.66 µmol/L | HeLa | Increased: Bax, p53, ROS; activation of caspase 3 and 9; Decreased: Bcl-2, AKT, MMP, G2/M cell block |
|                 | Fisetin       | IC<sub>50</sub> = 36.0 ± 0.5 µmol/L | HeLa | Increased: ERK1/2, activation of caspase 3 and 8; Decreased: tumor growth, with inhibition rates of 82.65% and 92.62%; |
|                 | Epigallocatechin gallate | IC<sub>50</sub> = 20 µmol/L | HeLa | Increased: Bax, p53, ROS; Cyt c release; Decreased: Bcl-2, COX-2, inhibition AKT and NF-κB; |
Table 1. Cont.

| Chemical Family | Molecule Name | Concentration | Cell Line | Mechanism |
|-----------------|---------------|---------------|-----------|-----------|
| Isoflavones     | Genistein     | IC₅₀ = 20 and 60 µmol/L | HeLa and CaSki | Increased: p38 MAPK, p38-JNK; Decreased: ERK1/2, AKT |
|                 |               | 20 mg/kg       | C57BL/6 cervical cancer cell mice model | Decreased: tumor growth |
|                 | Puerarin      | 12.5–50 µmol/L | HeLa      | Increased: Bax; Decreased: Wnt/β-catenin, p21, p53, Bcl-2 |
|                 |               | 0–2000 µmol/L  | cervical cancer cell line U14 mice models | Increased: IL-2, SOD; Decreased: tumor growth |
|                 | Formononetin  | 0–100 µmol/L   | HeLa      | Increased: Bax; Decreased: Bcl-2, MR1 and MR2, MMP |
|                 |               | 20 and 40 mg/kg for 35 d | Xenografts of cervical cancer HeLa cells in BALB/c nude mice | Decreased: tumor growth |
|                 | Cyanidin 3-O-glucoside | 400 µmol/L | HeLa | Increased: Bax, p53, TIMP-1; Decreased: Bcl-2, cyclin D1; G2/M phase cell block; PI3K/AKT/mTOR |

4. Terpenoids

4.1. Monoterpenoids

Paeoniflorin, a natural monoterpenyl glycoside compound, is the most important active component of the Chinese medicinal herb *Paeonia lactiflora* and has various protective effects on the cardiovascular system as mediating anti-inflammatory, antioxidant, apoptotic and autophagic regulation [110,111]. Recently, it has been found that paeoniflorin dose- and time-dependently inhibited the proliferation of human endometrial cancer RL95-2 cells by activating p38 MAPK and NF-κB signaling pathways [112]. It also inhibited the proliferation of human gastric cancer MGC-803 cells by inducing apoptosis through upregulation of miR-124 (miR-124) and inhibition of PI3K/AKT and transcription activator 3 (STAT3) signaling pathway [113]. In addition, the growth inhibition rate of paeoniflorin on human cervical cancer HeLa cells showed a concentration- and time-dependent relationship, with IC₅₀ values of 5054, 2965 and 2459 µg/mL for 24, 48 and 72 h of treatment. It increased Bax/Bcl-2 ratio and mitochondrial outer membrane permeability, caused the release of Cyt c into the cytoplasm, and activated Apaf-1 and caspase 3/9, which induced apoptosis in HeLa cells [114], and it is considered as a potential agent for the treatment of cervical cancer.

Carvacrol is a monoterpenyl phenol produced by many aromatic plants, including thyme, oregano and other plants. It has various biological and pharmacological properties, such as antibacterial, anticancer, anti-inflammatory, hepatoprotective, antispasmodic and vasodilator properties [115,116]. Carvacrol dose-dependently enhanced cytotoxicity in HeLa cells with IC₅₀ value of 556 ± 39 µmol/L after 24 h treatment. In addition, the cytotoxicity of carvacrol was further increased by MEK inhibitor PD325901, which inhibited ERK and increased the levels of LC3β-1/II. Carvacrol induced apoptosis through promoting caspase 9 expression and PARP cleavage [117]. Moreover, carvacrol induced cell-cycle arrest by increasing p53 expression and decreasing cyclin D1 expression in HeLa cells [118]. It may be a promising adjuvant therapeutic agent.

4.2. Sesquiterpenoids

In recent years, artemisinin and its derivatives (e.g., dihydroartemisinin and artemesunate) have been recognized as effective antimalarial agents [119]. They also have anticancer and anti-angiogenic properties with cytotoxic effects against several cancer types in vitro and in vivo [120–122]. Dihydroartemisinin inhibited the proliferation of HeLa and Caski cells in a dose- and time-dependent manner with IC₅₀ values of 22.08 and 18.20 µmol/L, respectively. It induced apoptosis through upregulation of Raf kinase...
inhibitor protein (RKIP) and downregulation of Bcl-2. In a BALB/c mouse model inoculated with HeLa cells or Caski cells, intraperitoneal injection of dihydroartemisinin for 3 weeks significantly inhibited tumor growth with inhibition rates among 70–80% [123]. Moreover, dihydroartemisinin induced apoptosis in HeLa cells and human endometrial cancer cells by decreasing the expression of Tfr mRNA and increasing the expression of caspase 3 mRNA. It also led to an increase in LC3-I/II ratio and a decrease in p62 protein levels, which induced autophagic pathway-mediated cell death. The inhibition of the autophagic pathway by using 3-MA further enhanced the cytotoxicity of dihydroartemisinin to HeLa cells [124]. In addition, dihydroartemisinin promoted the production of ROS by upregulating γH2AX protein and foci formation, led to DNA double-strand breaks, while upregulated the phosphorylation of Bcl-2 (Ser70) and mTOR (Ser2448), increased expression of the pro-autophagic protein Beclin-1 and induced autophagic death of Hela cells [125]. Zhang et al. found that dihydroartemisinin significantly inhibited the cell viability of HeLa cells by upregulating the expression of caveolin 1 (Cav1) and mitochondrial carrier homolog 2 (MTCH2) to activate p53 and decrease NQO1 expression, which contributed to the activation of the cell-death pathway and promoted apoptosis in HeLa cells [126].

Artesunate effectively enhanced TRAIL-mediated cytotoxicity by reducing the expression of pro-survival proteins (survivin, XIAP and Bcl-xl) via inhibiting the activation of NF-κB and AKT, and increased apoptosis induced by TRAIL [127]. Besides, artesunate dose-dependently inhibited HeLa and SiHa cell proliferation with IC50 values of 5.47 and 6.34 µmol/L, respectively. Interestingly, artesunate in vitro and in vivo increased the radiosensitivity of HeLa cells by promoting apoptosis and G2/M phase transition induced by X-ray irradiation, which was related with the increased expression of cytosolic cyclin B1. It was suggested that it could be applied as an effective radiosensitizer in cancer therapy [128]. Meanwhile, artesunate inhibited cell proliferation by suppressing COX-2 expression in HeLa and CaSki cells, and it decreased PGE2 production and the percentage of CD4+CD25+Foxp3+ T cells [129]. It was reported that subcutaneous injection of 100 mg/kg of artesunate for 15 d effectively reduced the growth and angiogenesis of xenograft tumors by suppressing the secretion of VEGF and the expression of vascular endothelial growth factor receptor KDR/flk-1 on tumors [130]. The results indicate that dihydroartemisinin and artesunate are promising candidates for cervical cancer treatment.

4.3. Diterpenoids and Terperpenoids

Tanshinone IIA is a diterpenoid naphthoquinone found in traditional Chinese medicine Salvia miltiorrhiza. It has anti-inflammatory and antioxidant activities and has been commonly used in prevention and treatment of cardiovascular disease [131,132]. Radha et al. found that tanshinone IIA caused a significant increase in the expression of p53, p21cip1/waf1, pRb and p130, and activated p53-dependent anticancer activity by inhibiting the expression of HPV E6 and E7 proteins, leading to growth inhibition of cervical cancer cells. In preclinical studies, intraperitoneal injection of 30 mg/kg of tanshinone IIA for 8 weeks significantly reduced the expression of the proliferation marker PCNA in tumor tissues and the volume of cervical cancer transplanted tumors in nude mice by more than 66% [133]. In addition, tanshinone IIA also reduced glycolysis by inhibiting intracellular AKT/mTOR and HIF-1α activities. In vivo, intraperitoneal injection of 40 mg/kg of tanshinone IIA, administered every 2 d for 20 d, effectively inhibited tumor growth and metastasis in U14 cervical cancer mice with an inhibition rate of 72.7% [134]. Another study found that tanshinone IIA inhibited the proliferation of HeLa, SiHa, CaSki and C33A cells in a dose-dependent manner with IC50 values of 6.97, 14.47, 5.51 and 9.89 µmol/L respectively, and showed a higher anti-proliferative effect than paclitaxel (18.45 µmol/L). Furthermore, tanshinone IIA treatment activated caspase 9 and 3 to cleave PARP, increased the ratio of Bax/Bcl-2 and JNK, released Cyt c that interacted with Apaf-1, and phosphorylated p38 to trigger ER stress-mediated apoptosis through IRE1 and PERK-related pathways. Notably, tanshinone IIA could improve paclitaxel chemosensitivity, suggesting
that it may be a potential strategy to overcome paclitaxel resistance [135]. Importantly, tanshinone IIA inhibited the migration and invasion of cervical cancer stem cells (CSCs) by inhibiting the transfer of HuR from the nucleus to the cytoplasm to reduce the stability and transcriptional activity YAP gene. It was also found that tanshinone IIA not only directly killed the activity of cervical CSCs, but also restored the sensitivity of cervical CSCs to adriamycin [136]. It can be used as an effective therapeutic agent for treating patients with cervical cancer and chemotherapy resistance.

Oridonin is an active diterpene isolated from *Rabdosia rubescens* with various pharmacological and physiological effects, including antibacterial, anti-inflammatory and antitumor [137]. Oridonin as an AKT inhibitor suppressed the growth of cancer cells by attenuating AKT signaling [138]. Hu et al. reported that oridonin inhibited the cell viability of HeLa cells in a dose- and time-dependent manner with an IC$_{50}$ value of 4.13 µmol/L (48 h) [139]. Several studies have shown that oridonin induced apoptosis involving multiple molecular pathways. It significantly inhibited the activity of constitutively activated targets of PI3K (Akt, forkhead box O protein (FOXO) and GSK3) in HeLa cell lines. Treatment of HeLa cells with oridonin activated the cell-death pathway by downregulating Akt kinase signaling, causing loss of MMP to trigger Cyt c release from the mitochondria, leading to downstream activation of caspase 9, caspase 3 and downregulating the expression of the survival proteins (cIAP1, XIAP and survivin), which led to cervical cancer cell death [140,141]. Additionally, ROS is the initiation signal for mitochondrial and caspase-dependent apoptosis as well as autophagy. Oridonin induced ROS production in HeLa cells in a dose-dependent manner, significantly increased Bax and caspase 8 and decreased pro-caspase 3, pro-caspase 9 and Bcl-2, which induced apoptosis and autophagy in HeLa cells [142]. Oridonin also induced apoptosis in HeLa cells through downregulating the level of p-AKT protein and inhibiting the expression and activity of cellular telomerase FKHRL and GSK3β [143]. It may be a key drug in the treatment of cervical cancer.

Ginsenoside Rh2 is a biologically active compound derived from ginseng and has various health effects, including stimulation of immune function, enhancement of cardiovascular health and anti-stress capacity [144]. Ginsenoside Rh2 activated mitochondria-dependent apoptosis pathway and inhibited mitochondrial oxidative phosphorylation and glycolysis in HeLa cells. In addition, ginsenoside Rh2 inhibited energy metabolism and induced apoptosis in HeLa cells by upregulating voltage-dependent anion channel 1 (VDAC1), which caused MMP depolarization and ROS production [145]. It is suggested that VDAC1 is a new target of ginsenoside Rh2. Ginsenoside Rh2 inhibited Hela cell proliferation in a dose- and time-dependent manner by targeting the Akt pathway, and prevented HeLa cell migration and invasion by inhibiting Akt/GSK3β, Snail expression and EMT occurrence [146]. Besides, the combination of ginsenoside Rh2 and betulinic acid induced Bax translocation to mitochondria and released Cyt c, activated caspase 8 and Bid cleavage, and sensitized tumor cells through Bax-dependent mechanism, which decreased cell viability and induced apoptosis [147]. Therefore, ginsenoside Rh2 has the potential to be a novel anticancer drug for cervical cancer.

Betulinic acid, a natural pentacyclic triterpene found in white birch bark, is one of the most promising cancer therapeutic compound with protective effects against tumor progression, inflammation, metabolic diseases and cardiovascular diseases [148,149]. Betulinic acid induced apoptosis in HeLa cells through modulation of PI3K/AKT and mitochondrial pathways. It dose-dependently inhibited the viability of HeLa cells with an IC$_{50}$ value of 30.42 ± 2.39 µmol/L at 48 h of treatment, the phosphorylation of AKT at Thr308 and Ser473, activated Bad, caspase 9 and cell-cycle regulatory factors p27Kip and p21Waf1/Cip1, and induced cell-cycle arrest at G0/G1 phase [150]. Betulinic acid also mediated the accumulation of HIF-1α and inhibited expression of HIF target genes VEGF, GLUT1 and PDK1 in HeLa cells by directly activating proteasome β1, β2 and β5 [151]. Further, betulinic acid decreased Bcl-2 and cyclin D1 and increased the expression of Bax genes, which induced apoptosis and inhibited cell proliferation and migration [152]. It has been shown that
betulinic acid is not toxic in vivo at a maximum dose of 500 mg/kg [153]. Betulinic acid is expected to be an adjuvant candidate for human cancer therapy shortly.

The chemical structures of terpenoids are summarized in Figure 2. Table 2 summarizes their effects and mechanisms on cervical cancer.

### Table 2. Effect of terpenoids on cervical cancer.

| Chemical Family | Molecule Name   | Concentration | Cell Line          | Mechanism                                                                 |
|-----------------|-----------------|---------------|--------------------|---------------------------------------------------------------------------|
| Monoterpenoids  | Paonilflorin    | IC₅₀ = 2459 µg/mL | HeLa               | Increased: Bax, Apat-1; activation of caspase 3; Cyt c release            |
|                 | Carvacrol       | IC₅₀ = 556 ± 39 µmol/L | HeLa               | Increased: LC3β-1-II; activation of caspase 3; PARP cleavage; Decreased: Bcl-2 |
|                 | Dihydroartemisin | IC₅₀ = 22.08 and 18.20 µmol/L | HeLa and Caski    | Increased: RRIP; Decreased: Bcl-2                                        |
|                 | Artesunate      | 60 µg/mL       | HeLa               | Increased: AKT; activation of caspase 3; PARP cleavage; p53, p21, p130, Bcl-2; Decreased: E6, E7 |
|                 |                 | 100 mg/kg for 15 d | Xenografts of cervical cancer HeLa or Caski cells in BALB/c mice | Decreased: tumor growth, inhibition of angiogenesis |
| Sesquiterpenoids| Tanshinone IIA  | IC₅₀ = 6.97, 14.47, 5.51, and 9.89 µmol/L | HeLa, SiHa, CaSki and C33A | Increased: Bax, PERK, IRE1, p38, JNK; activation of caspase 3 and 9; PARP cleavage; Cyt c and Ca²⁺ release; Decreased: Bcl-2 |
|                 | Oridonin        | 0–10 µmol/L    | HeLa, SiHa, CaSki  | Increased: p53, p21, p130, pRB; Decreased: E6, E7                        |
|                 |                 | 40 mg/kg for 20 d | Cervical cancer cell line U14 mice models | Decreased: metastasis and tumor growth with inhibition rates of 72.7% |
| Diterpenoids    | Ginsenoside Rh2 | C₅₀ = 35 µmol/L | HeLa               | Increased: Bax, ROS, VDAC1; Cyt c release; Decreased: MMP                |
|                 | Betulinic acid  | C₅₀ = 30.42 ± 2.39 µmol/L | HeLa               | Increased: Bad, ROS, p27⁰⁰⁰⁰ and p21⁰⁰⁰⁰; activation of caspase 9; Decreased: G0/G1 phase cell block; Inhibit PI3K/Akt   |
5. Alkaloids

5.1. Piperine

Piperine is a nitrogenous stimulant found in the fruits of black pepper and long pepper. It has various pharmacological properties in vitro and in vivo, such as anticancer, antibacterial, antiulcer hepatoprotective and immunomodulatory properties [154,155]. Asif et al. showed that piperine treatment at 50, 100 and 200 µmol/L dose-dependently reduced the cell viability of HeLa cells to 69.90%, 49.27% and 33.54%, respectively. Piperine inhibited HeLa cell proliferation by increasing ROS production and nuclear cohesion, delaying wound healing and blocking the G2/M phase cell cycle. In addition, piperine induced apoptosis in HeLa cells by disrupting MMP and activating caspase-3 [156]. Recently, it has been shown that piperine has the potential to reverse drug resistance in human cervical cancer cells. Piperine (50 µmol/L) downregulated Mcl-1, phosphorylated AKT and cooperated with paclitaxel to increase paclitaxel-induced apoptosis of drug-resistant cervical cancer cells [157]. Apart from this, piperine inhibited Bcl-2 signaling pathway and increased Bid, caspase and PARP activities by blocking STAT3/NF-κB, thereby enhancing therapeutic and antiproliferative effects of mitomycin C (MMC) on drug-resistant HeLa/MMC cells [158]. Consequently, the combination of these two drugs can effectively reduce tumor growth in vivo and is a potential anticancer agent for treating human cervical cancer.

5.2. Matrine

*Sophora flavescens* is a kind of Chinese medicine and contains active ingredient matrine. Because of its wide range of pharmacological effects, it has been considered as anticancer drug in China. It has been used clinically to treat viral hepatitis, neuropathic pain, heart disease, skin diseases and other disorders for a long time [159,160]. *S. flavescens* inhibits cervical-cancer-cell proliferation and metastasis and induces apoptosis by inhibiting the AKT/mTOR signaling pathway; reducing the expression of Bcl-2, cyclin A and MMP2; blocking the G2/M phase cell cycle; and stimulating Bax and E-cadherin. Matrine reduces vasodilator-stimulated phosphoprotein (VASP) phosphorylation by inhibiting protein kinase A (PKA) activity, thereby inhibiting HeLa cell adhesion and migration [161]. Besides, in mice injected with HeLa cells, intraperitoneal injection of matrine with 50 mg/kg/d for 21 d effectively inhibited the growth of cervical cancer xenografts with an inhibition rate of 58.33%. It also reduces the expression activity of extracellular matrix factors MMP2 and MMP9 by downregulating the p38 signal pathway, thus inhibiting the proliferation, metastasis and invasion of cervical cancer cells [162]. Matrine has the potential for development as therapeutic or adjuvant agent for human cervical cancer.

5.3. Berberine

Berberine, an isoquinoline alkaloid extracted from the herb, has various biological activities, such as antibacterial, anti-inflammatory, antidiabetic, anti-angiogenic and anticancer effects. It is widely used as an antibacterial agent in clinical practice [163,164]. Berberine inhibited the proliferation of HeLa and SiHa cells in a dose-dependent manner. It reduced cell viability and hTERT expression through a mitochondria-mediated pathway and activated caspase3, thereby inducing apoptosis. Moreover, berberine can selectively inhibit the transcription factor Activator Protein-1 (AP-1) activity and the transcription of HPV oncoproteins E6 and E7 and increase the expression of p53 and Rb to play an anti-cervical-cancer effect [165]. A study showed that berberine inhibited the invasion of SiHa cells by reducing the transcriptional activity of MMP2 and u-PA, mediated the downregulation of TGF-β1 expression and inhibited the angiogenic potential of SiHa cells. Notably, berberine (20 mg/kg/d for 21 d by oral gavage) was able to downregulate the NF-κB signaling pathway, increase E-cadherin expression and selectively inhibit snail-1 gene expression, thereby reversing EMT and reducing cancer cell growth and lung metastasis [166]. It was also found that the IC₅₀ value of berberine was 300 µmol/L after the 48-h treatment of HeLa cells. Berberine activated the death receptor pathway in HeLa cells by upregulating Fas, FasL, TNF-α and TRAF-1. Simultaneously, berberine
induced apoptosis in HeLa cells by activating the mitochondrial pathway, releasing Cyt c and significantly increasing the ratio of Bax/Bcl-2, which blocked the cell cycle at the S phase. Moreover, berberine activated the MAPK pathway and increased p53 expression, suggesting that p53 may be a drug target in the treatment of cervical cancer [167]. In addition, N-Mannich bases of berberine (methoxy functional group, acid functionality and cyano group), berberine analogs, had significant cytotoxicity in cervical cancer HeLa and CaSki cells [168]. It suggested the potential antitumor effect of berberine and its analogs on cervical cancer cells.

The chemical structures of alkaloids are summarized in Figure 3. Table 3 summarizes their effects and mechanisms on cervical cancer.

**Figure 3.** Chemical structure of several alkaloids in anti-cervical-cancer.

**Table 3.** Effect of alkaloids on cervical cancer.

| Chemical Family | Molecule Name | Concentration | Cell Line | Mechanism |
|-----------------|---------------|---------------|-----------|-----------|
| Alkaloids       | Piperine      | 0–200 μmol/L  | HeLa      | Increased: ROS; activation of caspase 3 Decreased: MMP; G2/M phase cell block |
|                 | Matrine       | 50 mg/kg for 21 d | Xenografts of cervical cancer HeLa cells in BALB/c nude mice | Decreased: p38, MMP2 and 9; tumor growth with inhibition rates of 58.33% |
|                 | Berberine     | IC_{50} = 300 μmol/L | HeLa | Increased: Bax, Fas, FasL, TNF-α, TRAF-1, p53, MAPK; DNA fragmentation; activation of caspase 3 Decreased: Bcl-2; S phase cell block |
|                 |               | 0–250 μg/mL   | HeLa and SiHa | Increased: p53, pRb Decreased: E6, E7, AP-1, c-Jun, c-Fos |

6. Phenols
6.1. Curcumin

Curcumin is a phenol compound extracted from the rhizome of the perennial herb turmeric in Zingiberaceae, and has been commonly used as a spice and food coloring. Its safety and efficacy as a traditional herbal medicine have been shown in previous studies. It also exerts anticancer effects through various mechanisms, including inhibition of cell proliferation, invasion and metastasis, and epigenetic alterations [169,170]. Curcumin directly inhibited telomerase activity in HeLa, SiHa and CaSki cells in a dose-dependent manner, induced Cyt c release, activated AIF and inhibited cyclin D1 and Ras proteins, thereby downregulating downstream targets of the Ras/Raf pathway and ultimately triggering apoptosis via the mitochondrial pathway. Curcumin also mediates the anti-proliferative and anti-inflammatory activities of cervical cancer cells by inhibiting COX-2 and inducible nitric oxide synthase (iNOS) expression and activating caspase 3 and caspase 9 [171]. It has been reported that oral gavage of curcumin (500, 1000 and 1500 mg/kg/d) for 30 d in a mouse model injected with CaSki cells significantly inhibited tumor-cell growth (21.03%) and the expression of VEGF and EGFR, which inhibited angiogenesis [172]. In addition, curcumin inhibited the proliferation of HeLa, CaSki, C33A and ME180 cells in a time- and concentration-dependent manner; and it activated ER-resident unfolded protein response (UPR) sensors (PERK, IRE-1a and ATF6) and their downstream signaling proteins in cervical cancer cells, especially CHOP. Activation of CHOP elevated the Bax/Bcl-2 ratio and increased ROS production, which induced apoptosis in cervical cancer cells [173]. On the other hand, curcumin induced G2/M-phase cell-cycle arrest and triggered cell autophagy and apoptosis through downregulation of cyclin B1 and Cdc25. At the same time, it mediated cellular senescence by elevating the p53/p21 pathway [174]. Furthermore,
curcumin treatment effectively reduced P-gp expression and increased the sensitivity of drug-resistant KB-V1 cells to vinblastine [175]. To enhance the bioavailability of curcumin, Warayuth et al. developed a delivery vehicle for oral curcumin. The cytotoxicity test showed that the IC\textsubscript{50} values of drug-loaded (curcumin) micelles on HeLa, SiHa and C33a cell lines were 4.7, 3.6 and 12.2 times lower than those of free curcumin (21.17, 16.28 and 54.29 µmol/L). Compared with free curcumin, the number of micelles carrying curcumin is significantly increased by 6-fold. It is worth noting that the percentage of early apoptosis of HeLa, SiHa and C33a cells is increased by curcumin micelles to 30–55% [176]. These data provide a possible theoretical basis for clinical application of cervical cancer.

6.2. Ellagic Acid

Ellagic acid is a natural phenol compound primarily found in fruits and nuts, including raspberries, pomegranates and walnuts, with strong anti-proliferative, anti-metastatic and anti-angiogenic activities [177,178]. Ellagic acid inhibited SiHa cell proliferation in a dose-dependent manner with an IC\textsubscript{50} value of 48.7 ± 2.5 µmol/L. Ellagic acid promoted SiHa cell apoptosis by upregulating p53, Bcl-2 and caspase 3/9; downregulating Bax; and inducing the G2-phase cell-cycle arrest [179]. Li et al. reported that ellagic acid induced G1-phase cell-cycle arrest by inhibiting the activation of janus kinase 2 (JAK2)/STAT3 pathway and downregulating the expression of Cyclin D1, Bcl-xl and Mcl-1, which in turn promoted apoptosis [180]. Moreover, ellagic acid inhibits the AKT/mTOR signaling pathway by increasing insulin-like growth factor-binding protein 7 (IGFBP7), thereby suppressing HeLa cell proliferation and invasion [181]. A recent study showed that treatment of HeLa cell with ellagic acid, curcumin and their combination for 72 h resulted in IC\textsubscript{50} values of 19.47, 16.52 and 10.9 µmol/L, which revealed the synergistic anticancer effect of ellagic acid and curcumin. Their combination synergistically restored p53 protein expression, induced ROS formation and increased DNA damage, accompanied by increased expression of the downstream effectors p21 and Bax, which induced apoptosis in HeLa cells [182]. Ellagic acid has the potential to be an ideal drug for the treatment of cervical cancer.

6.3. Resveratrol

Resveratrol is a dietary polyphenol derived from grapes, berries, peanuts and other plant sources. It has several potential biological effects, including cancer prevention and treatment [183]. Resveratrol inhibited the proliferation of HeLa and CaSki cells in a dose- and time-dependent manner with IC\textsubscript{50} values of 40.06 and 59.07 µmol/L at 72 h. Resveratrol inhibited HeLa and CaSki cell growth and development by inhibiting the expression of HPV oncoproteins E6 and E7; promoting p53, Bax and p16; and inducing cell-cycle arrest at the G1/S phase [184]. A study proved that resveratrol inhibited cervical cancer cell proliferation by upregulating suppressors of cytokine signaling 3 (SOCS3) and activated STAT3 (PIAS3) expression, blocking the DNA-binding activity of STAT3 and causing STAT3 inactivation [185]. Furthermore, resveratrol suppressed the degradation of EMT and extracellular matrix (ECM) by inhibiting STAT3 (Tyr705) phosphorylation [186]. He et al. found that resveratrol induced apoptosis in HeLa cells by downregulating hTERT mRNA and protein levels, which in turn inhibited telomerase activity [187]. Importantly, resveratrol also inhibited the expression of HIF-1α and VEGF in cervical cancer cells by blocking ERK1/2 and PI3K/Akt signaling pathways, thereby effectively reversing the angiogenic activity induced by HPV-16 E6 and E7 oncoproteins [188]. Another experiment proved that intraperitoneal injection of 10 mg/kg of resveratrol for 28 d significantly inhibited the growth of xenograft tumors in nude mice. Resveratrol significantly decreased the mRNA and protein expression of phospholipid scramblase 1 (PLSCR1), thereby inhibiting the proliferation and development of HeLa cells. In addition, resveratrol also inhibited migration and invasion of HeLa cells by suppressing NF-κB and AP-1-mediated MMP9 expression [189]. Resveratrol offers potential therapeutic value for the treatment of cervical cancer.
The chemical structures of phenols are summarized in Figure 4. Table 4 summarizes their mechanisms in cervical cancer. Figure 5 outlines the mechanism of natural products against cervical cancer.

Figure 4. Chemical structure of several phenols against cervical cancer.

Table 4. Effect of phenols on cervical cancer.

| Chemical Family | Molecule Name | Concentration | Cell Line | Mechanism |
|-----------------|---------------|---------------|-----------|-----------|
| Phenols         | Curcumin      | 50 and 100 µmol/L | HeLa, SiHa and CaSki | Increased: AIF, activation of caspase 3 and 9; Cyt c release Decreased: COX-2, iNOS, cyclin D1; Inhibit Ras/Raf |
|                 |               | 500, 1000 and 1500 mg/kg | Xenografts of cervical cancer | Decreased: tumor growth, VEGF and EGFR |
|                 | Ellagic acid  | C50 = 48.7 ± 2.5 µmol/L | SiHa | Increased: Bcl-2, p53; activation of caspase 3 and 9 | Decreased: Bax; G2 phase cell block |
|                 |               | C50 = 40.06, 59.07 µmol/L | HeLa | Increased: Bax, p53, p16 | Decreased: G1/S phase cell block |
|                 | Resveratrol   | 5–250 µmol/L | HeLa and CaSki | Decreased: Inhibit PI3K/AKT, ERK1/2, VEGF, HIF-1α accumulation |
|                 |               | 10 kg/mg for 28 d | Xenografts of cervical cancer | Decreased: tumor growth |

Figure 5. Mechanism of natural products against cervical cancer. Baicalein inhibits Cyclin D1 expression through down-regulation of the Wnt/β-catenin pathway, which in turn inhibits cell proliferation. Genistein inhibits cell proliferation by activating the p38 MAPK pathway. It also induces apoptosis by inhibiting the PI3K/AKT-NF-κB pathway, which in turn induces apoptosis. Naringin promotes apoptosis by up-regulating the expression of Bax and caspase 3/9, which in turn promotes apoptosis. Kaempferol is pro-apoptotic by inhibiting PI3K/AKT and activating the p53 pathway. EGCG induces apoptosis by increasing ROS production and Bax/Bcl-2 expression. Berberine induces apoptosis by activating JNK and p53, while Curcumin promotes apoptosis by inducing Cyt c release, thereby downregulating the Ras/Raf pathway. Tanshinone IIA induces apoptosis through inhibition of AKT/mTOR and activation of the JNK pathway. Betulinic acid induces cell cycle arrest and apoptosis by activating caspase 9 and inhibiting the PI3K/AKT pathway. ↑: Upregulation, ↓: Downregulation.
7. Conclusions

The high mortality and morbidity rates of cervical cancer remain a primary challenge for scientific research. Although conventional treatments, such as radiotherapy and chemotherapy, are effective, the five-year survival rate of cervical cancer patients is meager and often ends in failure. Moreover, chemotherapy is prone to drug resistance and toxic side effects, causing great suffering to patients. In recent years, plant-derived natural products have been considered as the most promising candidates for oncology therapies. In 2010, Bar-Sela et al. [190] reported a review article on curcumin as an anticancer agent, reviewing and analyzing data from clinical trials focusing on colon and pancreatic cancer and summarizing the main anticancer mechanisms of curcumin, but the article was published relatively early, ten years ago. Therefore, there is a need for further exploration and systematic review and sorting of the latest effective antitumor studies. In 2019, Hsiao et al. reviewed the effects and potential mechanisms of Chinese herbal medicines on cervical cancer and classified them according to crude extracts and compounds, outlining their effects on induction of apoptosis and inhibition of migration in vitro and in vivo, but the number of compounds was small [191]. In 2021, Park et al. reviewed the therapeutic effects of a variety of natural products on cervical cancer and their mechanisms, including apoptosis, anti-angiogenesis, anti-metastasis, drug resistance and microRNA modulation. However, the inhibition of telomerase activity and enhancement of immune function were not included [192]. Our study reviewed 30 natural products that have antitumor effects on cervical cancer, which showed possible benefits in treating patients with cervical cancer through mechanisms, such as induction of apoptosis, inhibition of cell proliferation and angiogenesis (Figure 6). Therefore, the search for more readily available natural antitumor active ingredients and precursor drugs could provide effectively alternative or adjuvant treatment strategies for cancer patients.

Figure 6. Overview of signaling pathways against cervical cancer.
Plant-derived natural products, a rich treasure trove of drug resources, have driven the development of novel inhibitors with their unique mode of action and molecular structural diversity. They play an important role in human cancer therapy with high safety and low side effects. However, some unresolved issues limit the translation of plant-derived natural products to clinical applications. First, some have poor water solubility, which seriously affects bio-availability. Second, potential toxicity and adverse effects of plant-derived natural products are lack of sufficient evaluation in vivo and clinical trial data. Again, further research on the mechanism of natural antitumor drugs is still the direction of future efforts. We believe that, with additional research, plant-derived natural products will be indeed applied in clinical medicine.

**Funding:** This work was supported by the National Natural Science Foundation of China (32060229, 31860258, U1803381).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Guo, L.; Hua, K. Cervical Cancer: Emerging Immune Landscape and Treatment. *OncoTargets Ther.* **2020**, *13*, 8037–8047. [CrossRef] [PubMed]

2. Arbyn, M.; Xu, L.; Simoens, C.; Martin-Hirsch, P.P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. *Cochrane Database Syst. Rev.* **2018**, *5*, CD009069. [CrossRef] [PubMed]

3. José, F.X.B.; Quint, W.G.; Alemany, L.; Geraerts, D.T.; Klaustermeier, J.E.; Llovers, B.; Tous, S.; Felix, A.; Bravo, L.E.; Shin, H.-R.; et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. *Lancet Oncol.* **2010**, *11*, 1048–1056. [CrossRef]

4. Rogers, L.; Siu, S.S.N.; Luesley, D.; Bryant, A.; O Dickinson, H. Radiotherapy and chemoradiation after surgery for early cervical cancer. *Cochrane Database Syst. Rev.* **2012**, *5*, CD007583. [CrossRef] [PubMed]

5. Tambaro, R.; Scambia, G.; Di Maio, M.; Pisano, C.; Barletta, E.; Iaffaioli, V.R.; Pignata, S. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. *Crit. Rev. Oncol.* **2004**, *52*, 33–44. [CrossRef] [PubMed]

6. Mann, J. Natural products in cancer chemotherapy: Past, present and future. *Nat. Rev. Cancer* **2002**, *2*, 143–148. [CrossRef] [PubMed]

7. Aung, T.N.; Qu, Z.; Kortschak, R.D.; Adelson, D.L. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. *Int. J. Mol. Sci.* **2017**, *18*, 656. [CrossRef]

8. Harvey, A.L. Natural products in drug discovery. *Drug Discov. Today* **2008**, *13*, 894–901. [CrossRef]

9. Ouyang, L.; Luo, Y.; Tian, M.; Zhang, S.-Y.; Lu, R.; Wang, J.-H.; Okazaki, M. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. *Am. J. Cancer Res.* **2019**, *9*, 1517–1535.

10. Niemietz, R.J.; van Noord, E.; van Hoorn, D.E.; Boelens, P.G.; van Norren, K.; van Leeuwen, P.A. Flavonoids: A review of probable mechanisms of action and potential applications. *Am. J. Clin. Nutr.* **2001**, *74*, 418–425. [CrossRef] [PubMed]

11. Alseekh, S.; de Souza, L.P.; Benina, M.; Fernie, A.R. The style and substance of plant flavonoid decoration; towards defining both structure and function. *Phytochemistry* **2020**, *174*, 112347. [CrossRef]

12. Zhang, Q.; Yang, W.; Liu, J.; Liu, H.; Lv, Z.; Zhang, C.; Chen, D.; Jiao, Z. Identification of Six Flavonoids as Novel Cellular Antioxidants and Their Structure-Activity Relationship. *Oxid. Med. Cell. Longev.* **2020**, *2020*, 4150897. [CrossRef]

13. Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. *Proc. Nutr. Soc.* **2010**, *69*, 273–278. [CrossRef]

14. Khater, M.; Ravishankar, D.; Greco, F.; Osborn, H.M. Metal complexes of flavonoids: Their synthesis, characterization and enhanced antioxidant and anticancer activities. *Future Med. Chem.* **2019**, *11*, 2845–2867. [CrossRef]

15. Ma, Y.; Zeng, M.; Sun, R.; Hu, M. Disposition of Flavonoids Impacts their Efficacy and Safety. *Curr. Drug Metab.* **2015**, *15*, 841–864. [CrossRef]

16. Dinda, B.; Dinda, S.; Das Sharma, S.; Banik, R.; Chakraborty, A.; Dinda, M. Therapeutic potentials of baicalein and its aglycone, baicalin against inflammatory disorders. *Eur. J. Med. Chem.* **2017**, *131*, 68–80. [CrossRef]

17. Liao, H.; Ye, J.; Gao, L.; Liu, Y. The main bioactive compounds of *Scutellaria baicalensis* Georgi. for alleviation of inflammatory cytokines: A comprehensive review. *Biomed. Pharmacother.* **2021**, *133*, 110917. [CrossRef]

18. Cheng, C.-S.; Chen, J.; Tan, H.-Y.; Wang, N.; Chen, Z.; Feng, Y. *Scutellaria baicalensis* and Cancer Treatment: Recent Progress and Perspectives in Biomedical and Clinical Studies. *Am. J. Chin. Med.* **2018**, *46*, 25–54. [CrossRef]
20. Xia, X.; Xia, J.; Yang, H.; Li, Y.; Liu, S.; Cao, Y.; Tang, L.; Yu, X. Baicalein blocked cervical carcinoma cell proliferation by targeting CCND1 via Wnt/β-catenin signaling pathway. *Artif. Cells Nanomed. Biotechnol.* 2019, 47, 2729–2736. [CrossRef]

21. Wu, X.; Yang, Z.; Dang, H.; Peng, H.; Dai, Z. Baicalein Inhibits the Proliferation of Cervical Cancer Cells Through the GSK3β-Dependent Pathway. *Oncol. Res. Treat.* 2018, 26, 645–653. [CrossRef]

22. Li, J.; Ma, J.; Wang, K.S.; Mi, C.; Wang, Z.; Piao, L.X.; Xu, G.H.; Li, X.; Lee, J.J.; Jin, X. Baicalein inhibits TNF-α-induced NF-κB activation and expression of NF-κB-regulated target gene products. *Oncol. Rep.* 2016, 36, 2771–2776. [CrossRef]

23. Peng, Y.; Guo, C.; Yang, Y.; Li, F.; Zhang, Y.; Jiang, B.; Li, Q. Baicalein induces apoptosis of human cervical cancer HeLa cells in vitro. *Med. Mol. Rep.* 2014, 11, 2129–2134. [CrossRef]

24. Yu, X.; Lu, K.; Xia, J.; Mao, X. Baicalein induces HeLa cell growth inhibition by down-regulation of matrix metalloproteinases and activating extracellular signal-regulated kinase. *Clin. J. Cell. Mol. Immunol.* 2014, 30, 798–801.

25. Hu, J.; Wang, R.; Liu, Y.; Zhou, J.; Shen, K.; Dai, Y. Baicalein Represses Cervical Cancer Cell Growth, Cell Cycle Progression and Promotes Apoptosis via Blocking AKT/mTOR Pathway by the Regulation of cIcatI1/mR-19a-3p Axis. *OncoTargets Ther.* 2021, 14, 905–916. [CrossRef]

26. Yu, X.; Yang, Y.; Li, Y.; Cao, Y.; Tang, L.; Chen, F.; Xia, J. Baicalein inhibits cervical cancer progression via downregulating long non-coding RNA BDNL and its downstream P13 K/Akt pathway. *Int. J. Biochem. Cell Biol.* 2018, 94, 107–118. [CrossRef]

27. He, L.; Lu, N.; Dai, Q.; Zhao, Y.; Zhao, L.; Wang, H.; Li, Z.; You, Q.; Guo, Q. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. *Toxicology* 2013, 312, 36–47. [CrossRef]

28. Kim, M.S.; Bak, Y.; Park, Y.S.; Lee, D.H.; Kim, J.H.; Kang, J.W.; Song, H.-H.; Oh, S.-R.; Yoon, D.Y. Wogonin induces apoptosis by suppressing E6 and E7 expressions and activating intrinsic signaling pathways in HPV-16 cervical cancer cells. *Cell Biol. Toxicol.* 2013, 29, 259–272. [CrossRef]

29. Yang, L.; Zhang, H.-W.; Hu, R.; Yang, Y.; Qi, Q.; Lu, N.; Liu, W.; Chu, Y.-Y.; You, Q.-D.; Guo, Q.-L. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. *Biochem. Cell Biol.* 2009, 87, 933–942. [PubMed]

30. He, F.; Wang, Q.; Zheng, X.-L.; Yan, J.-Q.; Yang, L.; Sun, H.; Hu, L.-N.; Lin, Y.; Wang, X. Wogonin potentiates cisplatin-induced cancer cell apoptosis and accumulation of intracellular reactive oxygen species. *Oncol. Rep.* 2012, 28, 601–605. [CrossRef]

31. Madunić, J.; Madunic, I.V.; Gajski, G.; Popić, J.; Garaj-Vrhovac, V. Apigenin: A dietary flavonoid with diverse anticancer properties. *Cancer Lett.* 2018, 413, 11–22. [CrossRef]

32. Wang, W.; Yue, R.-F.; Jin, Z.; He, L.-M.; Shen, R.; Du, D.; Tang, Y.-Z. Efficiency comparison of apigenin-7-O-glucoside and trolox in antioxidative stress and anti-inflammatory properties. *J. Pharm. Pharmacol.* 2020, 72, 1645–1656. [CrossRef] [PubMed]

33. Liu, M.-M.; Ma, R.-H.; Ni, Z.-J.; Thakur, K.; Cespedes-Acuña, C.L.; Jiang, L.; Wei, Z.-J. Apigenin-7-O-glucoside promotes cell apoptosis through the PTEN/P13K/AKT pathway and inhibits cell migration in cervical cancer HeLa cells. *Food Chem. Toxicol.* 2020, 146, 111843. [CrossRef] [PubMed]

34. Souza, R.P.; Bonfim-Mendonça, P.D.S.; Gimenes, F.; Ratti, B.A.; Kaplum, V.; Bruschi, M.L.; Nakamura, C.V.; Silva, S.O.; Maria-Engler, S.; Consolaro, M.E.L. Oxidative Stress Triggered by Apigenin Induces Apoptosis in a Comprehensive Panel of Human Cervical Cancer-Derived Cell Lines. *Oxidative Med. Cell. Longev.* 2017, 2017, 1512745. [CrossRef] [PubMed]

35. Zhang, E.; Zhang, Y.; Fan, Z.; Cheng, L.; Han, S.; Che, H. Apigenin Inhibits Histamine-Induced Cervical Cancer Tumor Growth by Regulating Estrogen Receptor Expression. *Molecules* 2020, 25, 1960. [CrossRef]

36. Seelinger, G.; Merfort, I.; Schepm, C.M. Anti-Oxidant, Anti-Inflammatory and Anti-Inflammatory Activities of Luteolin. *Planta Med.* 2008, 74, 1667–1677. [CrossRef]

37. Lin, Y.; Shi, R.; Wang, X.; Shen, H.-M. Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy. *Curr. Cancer Drug Targets* 2008, 8, 634–646. [CrossRef]

38. Krič, M.; Alhosin, M.; Muller, C.D.; Gies, J.-P.; Chekhir-Ghedira, L.; Ghedira, K.; Mély, Y.; Bronner, C.; Mousli, M. *Limoniumstrum gugenianum* aqueous gall extract induces apoptosis in human cervical cancer cells involving p16INK4A re-expression related to UHRF1 and DNMT1 down-regulation. *J. Exp. Clin. Cancer Res.* 2013, 32, 30. [CrossRef]

39. Shi, R.-X.; Ong, C.-N.; Shen, H.-M. Luteolin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells. *Oncogene* 2004, 23, 7712–7721. [CrossRef]

40. Shao, J.; Wang, C.; Li, L.; Liang, H.; Dai, J.; Ling, X.; Tang, H. Luteoloside Inhibits Proliferation and Promotes Intrinsic and Extrinsic Pathway-Mediated Apoptosis Involving MAPK and mTOR Signaling Pathways in Human Cervical Cancer Cells. *Int. J. Mol. Sci.* 2018, 19, 1644. [CrossRef]

41. Horinaka, M.; Yoshida, T.; Shiraiishi, T.; Nakata, S.; Wakada, M.; Nakamichi, R.; Nishino, H.; Sakai, T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. *Biochem. Biophys. Res. Commun.* 2005, 333, 833–838. [CrossRef]

42. Bharti, S.; Rani, N.; Krishnamurthy, B.; Arya, D.S. Preclinical Evidence for the Pharmacological Actions of Naringin: A Review. *Planta Med.* 2014, 80, 437–451. [CrossRef] [PubMed]

43. Ghanbari-Movahed, M.; Jackson, G.; Farzaei, M.H.; Bishayee, A. A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies. *Front. Pharmacol.* 2021, 12, 639840. [CrossRef] [PubMed]

44. Chen, S.; Lin, R.; Hu, X.; Shi, Q.; Chen, H. Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells. *Acta Biochim. Pol.* 2020, 67, 181–188. [CrossRef]
45. Ramesh, E.; Alshatwi, A.A. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem. Toxicol. 2013, 51, 97–105. [CrossRef]

46. Zeng, L.; Zhen, Y.; Chen, Y.; Zou, L.; Zhang, Y.; Hu, F.; Feng, J.; Shen, J.; Wei, B. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF-xB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int. J. Oncol. 2014, 45, 1929–1936. [CrossRef] [PubMed]

47. Pandey, P.; Khan, F. A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits. Nutr. Res. 2021, 92, 21–31. [CrossRef] [PubMed]

48. de Oliveira, J.M.P.F.; Santos, C.; Fernandes, E. Therapeutic potential of hesperidin and its aglycone hesperetin: Cell cycle regulation and apoptosis induction in cancer models. Phytomedicine 2020, 73, 152887. [CrossRef] [PubMed]

49. Alshatwi, A.A.; Ramesh, E.; Periasamy, V.; Subash-Babu, P. The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. Fundam. Clin. Pharmacol. 2013, 27, 581–592. [CrossRef]

50. Wang, Y.; Yu, H.; Zhang, J.; Gao, J.; Ge, X.; Lou, G. Hesperidin inhibits HeLa cell proliferation through apoptosis mediated by endoplasmic reticulum stress pathways and cell cycle arrest. BMC Cancer 2015, 15, 682. [CrossRef]

51. Abenavoli, L.; Capasso, R.; Milic, N.; Capasso, F. Milk thistle in liver diseases: Past, present, future. Phytother. Res. 2010, 24, 1423–1432. [CrossRef]

52. Chu, C.; Li, D.; Zhang, S.; Ikejima, T.; Jia, Y.; Wang, D.; Xu, F. Role of silibinin in the management of diabetes mellitus and its complications. Arch. Pharmaceut. Res. 2018, 41, 785–796. [CrossRef] [PubMed]

53. You, Y.; He, Q.; Lu, H.; Zhou, X.; Chen, L.; Liu, H.; Lu, Z.; Liu, D.; Liu, Y.; Zuo, D.; et al. Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer. Front. Pharmacol. 2020, 11, 271. [CrossRef] [PubMed]

54. Garcia-Maceira, P.; Mateo, J.; Garcia, P. Silibinin inhibits hypoxia-inducible factor-1α and mTOR/P70S6K signalling pathway in human cervical and hepatoma cancer cells: Implications for anticancer therapy. Oncogene 2008, 28, 313–324. [CrossRef]

55. Zhang, Y.; Ge, Y.; Chen, Y.; Li, Q.; Chen, J.; Dong, Y.; Shi, W. Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem. Funct. 2011, 30, 243–248. [CrossRef] [PubMed]

56. Fan, S.; Li, L.; Chen, S.; Yu, Y.; Qi, M.; Tashiro, S-I.; Onodera, S.; Ikejima, T. Silibinin Induces G2/M Cell Cycle Arrest and Apoptosis on HeLa cells. Nutr. Res. 2011, 41, 1307–1324. [CrossRef] [PubMed]

57. Fan, S.; Qi, M.; Zhi, Y.; Li, L.; Yao, G.; Tashiro, S-I.; Onodera, S.; Ikejima, T. P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK. Free Radic. Res. 2012, 46, 310–319. [CrossRef] [PubMed]

58. Imran, M.; Rauf, A.; Shah, Z.A.; Saeed, F.; Imran, A.; Arshad, M.U.; Peters, D.G.; et al. Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review. Phytother. Res. 2019, 33, 263–275. [CrossRef]

59. Tu, L.-Y.; Bai, H.-H.; Cai, J.-Y.; Deng, S.-P. The mechanism of kaempferol induced apoptosis and inhibited proliferation in human cervical cancer SiHa cell: From macro to nano. Scanning 2016, 38, 644–653. [CrossRef]

60. Kashafi, E.; Moradzadeh, M.; Mohamadkhani, A.; Erfanian, S. Kaempferol increases apoptosis in human cervical cancer HeLa cells via PI3K/AKT and telomerase pathways. Biomed. Pharmacother. 2017, 89, 573–577. [CrossRef]

61. Kumar, A.; Jaitak, V. Natural products as multidrug resistance modulators in cancer. Eur. J. Med. Chem. 2019, 176, 268–291. [CrossRef]

62. Limtrakul, P.; Khantamat, O.; Pintha, K. Inhibition of P-Glycoprotein Function and Expression by Kaempferol and Quercetin. J. Chemother. 2005, 17, 86–95. [CrossRef]

63. Andres, S.; Pevny, S.; Ziegenhagen, R.; Bakhya, N.; Schäfer, B.; Hirsch-Ernst, K.I.; Lampen, A. Safety Aspects of the Use of Quercetin as a Dietary Supplement. Mol. Nutr. Food Res. 2018, 62, 1700447. [CrossRef]

64. Mkrus, L.; Batinić, J.; Bjelis, N.; Jakas, A. Synthesis and biological evaluation of quercetin and resveratrol peptidyl derivatives as potential anticancer and antioxidant agents. Amino Acids 2018, 51, 319–329. [CrossRef]

65. Sundaram, M.K.; Raina, R.; Afroz, N.; Bajbouj, K.; Hamad, M.; Haque, S.; Hussain, A. Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells. Biochem. Biophys. Res. 2019, 39, 39. [CrossRef] [PubMed]

66. Vidya Priyadarssini, R.; Senthil Murugan, R.; Maitreyi, S.; Ramalingam, K.; Karunagaran, D.; Nagini, S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κB inhibition. Eur. J. Pharmacol. 2010, 649, 84–91. [CrossRef] [PubMed]

67. Clemente-Soto, A.F.; Salas-Vidal, E.; Milan-Pacheco, C.; Sánchez-Carranza, J.N.; Peralta-Zaragoza, O.; González-Maya, L. Quercetin induces G2 phase arrest and apoptosis through the activation of p53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells. Mol. Med. Rep. 2019, 19, 2097–2106. [CrossRef] [PubMed]

68. Bishayee, K.; Ghosh, S.; Mukherjee, A.; Sadhukhan, R.; Mondal, J.; Khuda-Bukhsh, A.R. Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: Signal cascade and drug-DNA interaction. Cell Prolif. 2013, 46, 153–163. [CrossRef] [PubMed]
70. Xu, W.; Xie, S.; Chen, X.; Pan, S.; Qian, H.; Zhu, X. Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells. Drug Des. Dev. Ther. 2021, 15, 577–588. [CrossRef] [PubMed]

71. Jakubowicz-Gil, J.; Paduch, R.; Piersiak, T.; Glowiak, K.; Gawron, A.; Kandefer-Szerszyniak, T. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem. Pharmacol. 2005, 69, 1343–1350. [CrossRef]

72. Adhami, V.M.; Syed, D.N.; Khan, N.; Mukhtar, H. Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem. Pharmacol. 2012, 84, 1277–1281. [CrossRef]

73. Kashyap, D.; Sharma, A.; Sak, K.; Tuli, H.S.; Buttar, H.S.; Bishayee, A. Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy. Life Sci. 2018, 194, 75–87. [CrossRef]

74. Chou, R.-H.; Hsieh, S.-C.; Yu, Y.-L.; Huang, M.-H.; Huang, Y.-C.; Hsieh, Y.-H. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS ONE 2013, 8, e71983. [CrossRef]

75. Liu, L.-Q.; Guo, W.; Yu, W.-D.; You, Z.-S. Fisetin Simultaneously Targets Apaf-1, ERK, and COX-2 Signaling Leading to Growth Inhibition and Apoptosis in Human Cervical Carcinoma Cell In Vitro. J. Sun Yat-sen Univ. Med. Sci. 2013, 34, 75.

76. Ying, T.-H.; Yang, S.-F.; Tsai, S.-J.; Hsieh, S.-C.; Huang, Y.-C.; Bau, D.-T.; Hsieh, Y.-H. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8/- caspase-3-dependent pathway. Arch. Toxicol. 2012, 86, 263–273. [CrossRef]

77. Lin, M.-T.; Lin, C.-L.; Lin, T.-Y.; Cheng, C.-W.; Yang, S.-F.; Lin, C.-L.; Wu, C.-C.; Hsieh, Y.-H.; Tsai, J.-P. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumor Biol. 2015, 37, 6987–6996. [CrossRef] [PubMed]

78. Musial, C.; Kuban-Jankowska, A.; Gorska-Ponikowska, M. Beneficial Properties of Green Tea Catechins. Int. J. Mol. Sci. 2020, 21, 1744. [CrossRef] [PubMed]

79. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82, 1807–1821. [CrossRef] [PubMed]

80. Al-Hazzani, A.A.; Alshawi, A.A. Catechin hydrate inhibits proliferation and mediates apoptosis of SiHa human cervical cancer cells. Food Chem. Toxicol. 2011, 49, 3281–3286. [CrossRef] [PubMed]

81. Singh, M.; Singh, R.; Bhui, K.; Tyagi, S.; Mahmood, Z.; Shukla, Y. Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear-factor-kappaB and Akt activation in human cervical cancer cells. Oncol. Res. 2011, 19, 245–257. [CrossRef]

82. Panji, M.; Behmard, V.; Zare, Z.; Malekpour, M.; Nejadbiglari, H.; Yavazi, S.; Dizaj, T.N.; Safaeian, A.; Maleki, N.; Abbasi, M.; et al. Suppressing effects of green tea extract and Epigallocatechin-3-gallate (EGCG) on TGF-β- induced epithelial-to-mesenchymal transition via ROS/Smad signaling in human cervical cancer cells. Gene 2021, 794, 145774. [CrossRef]

83. Zhang, Q.; Tang, X.; Lu, Q.; Zhang, Z.; Rao, J.; Le, A.D. Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5, 1227–1238. [CrossRef]

84. Kiliaris, K.; Sahin, K.; Tuzcu, M.; Basak, N.; Orhan, C.; Elibol-Can, B.; Kiliaris, K.; Sahin, F.; Kucuk, O. Enhancement of Cisplatin sensitivity in human cervical cancer cell lines. Iran. J. Immunol. 2011, 8, 122–130. [CrossRef]

85. Yokoyama, M.; Noguchi, M.; Nakao, Y.; Pater, A.; Iwasaka, T. The tea polyphenol, (+)-epigallocatechin gallate induces growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol. Oncol. 2004, 92, 197–204. [CrossRef] [PubMed]

86. Dixon, R.A.; Ferreira, D. Genistein. Phytochemistry 2002, 60, 205–211. [CrossRef] [PubMed]

87. Ghaemi, A.; Soleimanjahi, H.; Razeghi, S.; Gorji, A.; Vakili, M.A. Genistein induces a pro-apoptotic activity of cisplatin in HeLa cells. Biochem. Pharmacol. 2005, 69, 1343–1350. [CrossRef]

88. Sahin, K.; Tuzcu, M.; Basak, N.; Caglayan, B.; Kilic, E.; Sahin, F.; Kucuk, O. Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells Through Estrogen Receptor-Mediated PI3K/Akt-NF-κB Pathway. J. Cancer Res. 2012, 6, 288–295. [CrossRef] [PubMed]

89. Molton, S.A.; Todd, D.E.; Cook, S.J. Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3-kinase (PI3K) pathway is inhibited. Oncogene 2003, 22, 4690–4701. [CrossRef] [PubMed]

90. Aguirre-Ghiso, J.A.; Estrada, Y.; Liu, D.; Ossowska, L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p53(SAPK). Cancer Res. 2003, 63, 1684–1695. [CrossRef]

91. Kim, S.-H.; Kim, Y.-B.; Jeon, Y.-T.; Lee, S.-C.; Song, Y.-S. Genistein Inhibits Cell Growth by Modulating Various Mitogen-Activated Protein Kinases and AKT in Cervical Cancer Cells. Ann. N. Y. Acad. Sci. 2009, 1171, 500–500. [CrossRef]

92. Hsieh, C.J.; Hsu, Y.L.; Huang, Y.F.; Tsai, E.M. Molecular Mechanisms of Anticancer Effects of Phytoestrogens in Breast Cancer. Curr. Protein Pept. Sci. 2018, 19, 323–332. [CrossRef]

93. Chen, H.-H.; Chen, S.-P.; Zheng, Q.-L.; Nie, S.-P.; Li, W.-J.; Hu, X.-J.; Xie, M.-Y. Genistein Promotes Proliferation of Human Cervical Cancer Cells Through Estrogen Receptor-Mediated PI3K/Akt-NF-κB Pathway. J. Cancer 2018, 9, 288–295. [CrossRef] [PubMed]

94. Zhu, J.; Zhang, C.; Qi, Y.; Cheng, Y.; Jiang, X.; Li, M.; Yang, Z.; Wang, N. Genistein induces apoptosis by stabilizing intracellular p53 protein through an APE1-mediated pathway. Free Radic. Biol. Med. 2015, 86, 209–218. [CrossRef] [PubMed]

95. Bharti, R.; Chopra, B.S.; Raut, S.; Khatri, N. A Review on Traditional Uses, Pharmacology, and Phytochemistry. Front. Pharmacol. 2020, 11, 582506. [CrossRef] [PubMed]
123. Hu, C.-J.; Zhou, L.; Cai, Y. Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2. Cancer Biol. Ther. 2013, 15, 279–288. [CrossRef] [PubMed]

124. Tang, T.; Xia, Q.; Xi, M. Dihydroartemisinin and its anticancer activity against endometrial carcinoma and cervical cancer: Involvement of apoptosis, autophagy and transferrin receptor. Singap. Med. J. 2021, 62, 96–103. [CrossRef]

125. Wang, L.; Li, J.; Shi, X.; Li, S.; Tang, P.M.K.; Li, Z.; Li, H.; Wei, C. Antimalarial Dihydroartemisinin triggers autophagy within HeLa cells of human cervical cancer through Bcl-2 phosphorylation at Ser70. Phytomedicine 2019, 52, 147–156. [CrossRef] [PubMed]

126. Zhang, T.; Hu, Y.; Wang, T.; Cai, P. Dihydroartemisinin inhibits the viability of cervical cancer cells by upregulating caveolin 1 and mitochondrial carrier homolog 2: Involvement of p53 activation and NAD(P)H-quinone oxidoreductase 1 downregulation. Int. J. Mol. Med. 2017, 40, 21–30. [CrossRef] [PubMed]

127. Thanaketpaisarn, O.; Waikut, P.; Sakurai, H.; Saiki, I. Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-κB and PI3K/Akt signaling pathways. Int. J. Oncol. 2011, 39, 279–285.

128. Luo, J.; Zhu, W.; Tang, Y.; Cao, H.; Zhou, Y.; Ji, R.; Zhou, X.; Lu, Z.; Yang, H.; Zhang, S.; et al. Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat. Oncol. 2014, 9, 84. [CrossRef]

129. Zhang, L.-X.; Liu, Z.-N.; Ye, J.; Sha, M.; Qian, H.; Bu, X.-H.; Luan, Z.-Y.; Xu, X.-L.; Huang, A.-H.; Yuan, D.-L.; et al. Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. Cell Biol. Int. 2014, 38, 639–646. [CrossRef]

130. Chen, H.-H.; Zhou, H.-J.; Wu, G.-D.; Lou, X.-E. Inhibitory Effects of Artesunate on Angiogenesis and on Expressions of Vascular Endothelial Growth Factor and VEGF Receptor KDR/Ik-1. Pharmacology 2004, 71, 1–9. [CrossRef]

131. Yen, J.-H.; Huang, S.-T.; Huang, H.-S.; Fong, Y.-C.; Wu, Y.-Y.; Chiang, J.-H.; Su, Y.-C. HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor efficacy of Tanshinone II A in human osteosarcoma cells. Cell Death Dis. 2018, 9, 1003. [CrossRef] [PubMed]

132. Li, Z.M.; Xu, S.W.; Liu, P.Q. Salvia miltiorrhizaBurge (Danshen): A golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol. Sin. 2018, 39, 802–824. [CrossRef]

133. Munagala, R.; Agil, F.; Jeyabalan, J.; Gupta, R.C. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Cancer Lett. 2015, 356, 536–546. [CrossRef]

134. Liu, Z.; Zhu, W.; Kong, X.; Chen, X.; Sun, X.; Zhang, W.; Zhang, R. Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer. Oncol. Rep. 2019, 42, 1893–1903. [CrossRef] [PubMed]

135. Pan, T.-L.; Wang, P.-W.; Hung, Y.-C.; Huang, C.-H.; Rau, K.-M. Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. Proteomics 2013, 13, 3411–3423. [CrossRef]

136. Qin, J.; Shi, H.; Xu, Y.; Zhao, F.; Wang, Q. Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity. Biomed. Pharmacother. 2018, 105, 758–765. [CrossRef]

137. Cheng, W.; Huang, C.; Ma, W.; Tian, X.; Zhang, X. Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities. Mini-Rev. Med. Chem. 2018, 19, 114–124. [CrossRef]

138. Song, M.; Liu, X.; Liu, K.; Zhao, R.; Huang, H.; Shi, Y.; Zhang, M.; Zhou, S.; Xie, H.; Chen, H.; et al. Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo. Mol. Cancer Ther. 2018, 17, 1540–1553. [CrossRef]

139. Zhang, Y.-N.; Zhang, Z.-Y.; Liu, H.-Y.; Wang, S.-H. Effects of oridonin on mitochondrial apoptotic pathway of human cervical carcinoma Hela cells. China J. Mod. Med. 2021, 31, 1–7.

140. Hu, H.-Z.; Yang, Y.-B.; Xu, X.-D.; Shen, H.-W.; Shu, Y.-M.; Ren, Z.; Li, X.-M.; Shen, H.-M.; Zeng, H.-T. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol. Sin. 2007, 28, 1819–1826. [CrossRef] [PubMed]

141. Zhang, C.-L.; Wu, L.-J.; Tashiro, S.-I.; Onodera, S.; Ikejima, T. Oridonin induced A375-S2 cell apoptosis VIA BAX-regulated caspase pathway activation, dependent on the cytochrome C/CASPASE-9 apotosome. J. Asian Nat. Prod. Res. 2004, 6, 127–138. [CrossRef]

142. Zhang, Y.-H.; Wu, Y.-L.; Tashiro, S.-I.; Onodera, S.; Ikejima, T. Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol. Sin. 2011, 32, 1266–1275. [CrossRef]

143. Shen, H.; Hu, H.; Zeng, H.; Ke, P.; Yang, Y.; Li, X.; Ren, Z. Oridonin Induces Apoptosis Via PI3K/AKT Pathway in Cervical Carcinoma HeLa Cell Line. J. Sun yat-sen Univ. Med. Sci. 2007, 28, 1819–1826.

144. Liu, Y.; Chu, S.; Lin, M.; Gao, Y.; Liu, Y.; Yang, S.; Zhou, X.; Zhang, Y.; Hu, Y.; Wang, H.; et al. Anticancer property of ginsenoside Rf2 from ginseng. Eur. J. Med. Chem. 2020, 203, 112627. [CrossRef]

145. Liu, Y.; Wang, J.; Qiao, J.; Liu, S.; Wang, S.; Zhao, D.; Bai, X.; Liu, M. Ginsenoside Rg2 inhibits HeLa cell energy metabolism and induces apoptosis by upregulating voltage-dependent anion channel 1. Int. J. Mol. Med. 2020, 46, 1695–1706. [CrossRef]

146. Shi, X.; Yang, J.; Wei, G. Ginsenoside 20(S)-Rg2 exerts anti-cancer activity through the Akt/GSK3β signaling pathway in human cervical cancer cells. Mol. Med. Rep. 2018, 17, 4811–4816. [CrossRef] [PubMed]

147. Li, Q.; Li, Y.; Wang, X.; Fang, X.; He, K.; Guo, X.; Zhan, Z.; Sun, C.; Jin, Y.-H. Co-treatment with ginsenoside Rb2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced caspase-8 activation, bax translocation, and cytochrome c release. Mol. Carcinog. 2011, 50, 760–769. [CrossRef]

148. Fulda, S. Betulinic acid: A natural product with anticancer activity. Mol. Nutr. Food Res. 2009, 53, 140–146. [CrossRef] [PubMed]

149. Rios, J.L.; Mañez, S. New Pharmacological Opportunities for Betulinic Acid. Planta Med. 2018, 84, 8–19. [CrossRef]
175. Anuchapreeda, S.; Leechanachai, P.; Smith, M.M.; Ambudkar, S.V.; Limtrakul, P.-N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 2002, 64, 573–582. [CrossRef]

176. Sajomsang, W.; Gonil, P.; Saeso, S.; Ruktanonchai, U.R.; Sirunanchai, W.; Puttipipatkhachorn, S. Synthesis and anticervical cancer activity of novel pH responsive micelles for oral curcumin delivery. Int. J. Pharm. 2014, 477, 261–272. [CrossRef] [PubMed]

177. Ceci, C.; Lacal, P.M.; Tentori, L.; De Martino, M.G.; Miano, R.; Graziani, G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients 2018, 10, 1756. [CrossRef]

178. Zhang, H.-M.; Zhao, L.; Li, H.; Xu, H.; Chen, W.-W.; Tao, L. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol. Med. 2014, 11, 92–100. [CrossRef]

179. Chen, W.; Shen, X.; Ma, L.; Chen, R.; Yuan, Q.; Zheng, Y.; Li, C.; Peng, G. Phenolic Compounds from Polygonum chinense Induce Growth Inhibition and Apoptosis of Cervical Cancer SiHa Cells. BioMed Res. Int. 2020, 2020, 8868508. [CrossRef]

180. Li, L.; Na, C.; Tian, S.; Chen, J.; Ma, R.; Gao, Y.; Lou, G. Ellagic acid induces HeLa cell apoptosis via regulating signal transducer and activator of transcription 3 signaling. Exp. Ther. Med. 2018, 16, 29–36. [CrossRef] [PubMed]

181. Guo, H.; Zhang, D.; Fu, Q. Inhibition of Cervical Cancer by Promoting IGFBP7 Expression Using Ellagic Acid from Pomegranate Peel. Med. Sci. Monit. 2016, 22, 4881–4886. [CrossRef] [PubMed]

182. Kumar, D.; Basu, S.; Parija, L.; Rout, D.; Manca, S.; Dandapat, J.; Debata, P.R. Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells. Biomed. Pharmacother. 2016, 81, 31–37. [CrossRef] [PubMed]

183. Bishayee, A. Cancer Prevention and Treatment with Resveratrol: From Rodent Studies to Clinical Trials. Cancer Prev. Res. 2009, 2, 409–418. [CrossRef] [PubMed]

184. Sun, X.; Fu, P.; Xie, L.; Chai, S.; Xu, Q.; Zeng, L.; Wang, X.; Jiang, N.; Sang, M. Resveratrol inhibits the progression of cervical cancer by suppressing the transcription and expression of HPV E6 and E7 genes. Int. J. Mol. Med. 2020, 47, 335–345. [CrossRef]

185. Zhang, P.; Yang, B.; Yao, Y.-Y.; Zhong, L.-X.; Chen, X.-Y.; Kong, Q.-Y.; Wu, M.-L.; Li, C.; Li, H.; Liu, J. PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling. Gynecol. Oncol. 2015, 139, 529–535. [CrossRef]

186. Sun, X.; Xu, Q.; Zeng, L.; Xie, L.; Zhao, Q.; Xu, H.; Wang, X.; Jiang, N.; Fu, P.; Sang, M. Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3 Tyr705 phosphorylation. Cancer Med. 2020, 9, 8685–8700. [CrossRef] [PubMed]

187. He, M.-J.; Yang, S.-Y.; Lu, J.; Han, S.-S.; Liu, R.; Lian, F.-Z. Effects of resveratrol on telomerase activity and gene expression in human cervical cancer HeLa cells. J. Hgg. Res. 2019, 48, 1001–1003.

188. Tang, X.; Zhang, Q.; Nishitani, J.; Brown, J.; Shi, S.; Le, A.D. Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Hypoxia-Inducible Factor 1α Protein Accumulation and Vascular Endothelial Growth Factor Expression in Human Cervical Carcinoma Cells. Clin. Cancer Res. 2007, 13, 2568–2576. [CrossRef] [PubMed]

189. Zhao, Y.; Yuan, X.; Li, X.; Zhang, Y. Resveratrol significantly inhibits the occurrence and development of cervical cancer by regulating phospholipid scramblase 1. J. Cell. Biochem. 2019, 120, 1527–1531. [CrossRef]

190. Epelbaum, R.; Schaffer, M. Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications. Curr. Med. Chem. 2010, 17, 190–197. [CrossRef]

191. Hsiao, Y.-H.; Lin, C.-W.; Wang, P.-H.; Hsin, M.-C.; Yang, S.-F. The Potential of Chinese Herbal Medicines in the Treatment of Cervical Cancer. Integr. Cancer Ther. 2019, 18, 1534735419861693. [CrossRef] [PubMed]

192. Park, S.-H.; Kim, M.; Lee, S.; Jung, W.; Kim, B. Therapeutic Potential of Natural Products in Treatment of Cervical Cancer: A Review. Nutrients 2021, 13, 154. [CrossRef] [PubMed]